

Assess effects of Tx/interventions.

Call for Help early.

personal safety.

patient responsiveness First impression.

witel signs.


Physiological parameter (Vital signs)	3		1 1	Score 0	1 1	2	3
Respiration rate (per minute)	≤8		9–11	12–20		21–24	≥25
SpO <sub>2</sub> Scale 1 (%)	<b>≤91</b> PaO2=60	92–93	94–95	≥96	Why doesn't reach Bcz of the physiol- and coronary veins	erical shunt e% from	n bronchial
SpO <sub>2</sub> Scale 2 (%) COPD pts (apnea risk)	≤83 PaO2= 55 (macrobi	84–85	86–87	88–92 ≥93 on air	93–94 on oxygen	95–96 on oxygen	≥97 on oxygen
Air or oxygen?		Oxygen		Air			
Systolic blood pressure (mmHg)	≤90 Shock	91–100	101–110	111–219			≥220
Pulse (per minute)	≤40		41–50	51–90	91–110	111–130	≥131
Consciousness				Alert GCS- 15		en Itspensi te vet Stirred	I ALL
Temperature (*C)	≤35.0		35.1–36.0	36.1–38.0	38.1–39.0	≥39.1	to points Grant

## Chart 2: NEWS thresholds and triggers

NEW score	Clinical risk	Response
Aggregate score 0–4	Low	Ward-based response
Red score score of 3 in any individual parameter	Low-medium	Urgent ward-based response*
Aggregate score 5–6	Medium	Key threshold for urgent response
Aggregate score 7 or more	High	Urgent or emergency response**


escalation of care to a critical care team is appropriate.


<sup>&</sup>quot;The response team must also include staff with critical care skills, including airway management.




· Cardiopulmonery arrest: cessetion of the spontanous function of Cvs or RS. · cardiopalmonary resuscitation: Artificial delivery of the oxygenated blood through the vescular beds of vital organs to maintain there functions. vital organs: - Brain, Heart, Kidney, Liver, Lungs. • BIS \_\_\_\_no equipment use Aim to keep ventilation & circulation - Golden min 3-4 min. Safety \_\_ check response \_\_ Response \_\_ yes \_\_ Leave Him - check resulary No - Help - open Airway - check B &C Head tilt ochin lift

Jaw thrust No pulse \_\_\_\_ Middle of starnum by nipples. external cardiac massage 30:2 breaths use heels of Hands -finger interlocked vertical above patient chest arms should be straight (Locked). 5-6cm, 100-120/min \_\_\_ CPR cycle = 15 (30:2) & 2 min. don't stop until \_\_\_ pt shows sign of Life. \_\_ CPR time arrives. \_\_you become exhausted. Recovery position (Lateral) uncounsciouss but breating & circulation restored. Benefits \_\_\_ maintain airway opening (tounge). prevent inhelation of Garric content. Notes if pulse restored but no Bresthing - stop CPR - 1 bresth /6 sec (8-12 b/min) , if the petient have Respiratory disease (covid) \_, ppg \_ \_ choking







• Perecello	causes of cardiac Arrest (5H,5T)
	Ensure girwey. Hyperalaemia Hyp
	Give t flow 02
	Avoid hyperventilation.
Hypovo laemia	History: Vomiting, dierrhia, bone Frecture
	Examination internal & external haemorrhage
	Surgical drains
	- control heemorchese
	(claemia & H+(acidosis) Near pt. testing: K & showse
Hypo/hyperk	(claemia & H+(acidoss) Near of tertins: K & ducise
ייבוניי וניי	check Lab results.
	HyperKalaemic(>55) calcium chlor
	Linsulin /dexter
	Indin/aexti
11 11	Hypo (K, Mg) Electrolyte supplement
- Hypothermia	Rere in in-patient
	wise Low reading thermometer.
	Tx with active rewarming techniques
	Consider cardiopalmonacy bypes.
	CPR - until 34°C - CPR for 30 min only.
_Tension pneum	notherax check tube position if intubated.
	-clinical signs - Breath Sounds
	Hyper-resonant percussion
5	Tracheal divation
	distended neck veins.
	initial Tx with needle decompression or thoracostomy
4 JEV	Initial IX with need to decompression of the recommy
	2nd ICS midcleviculer.
Echo	5th Ics midaxillary.
🛶 lamponade 🛨	dx by echo
	consider in chest trauma or after cardiac Surgery.
	Tx with needle pericardiocentesis or resuscitative thoracotomy
	Rare unless evidence of deliberate overdose.
	Tx:- antidate & Gastric Laveje.
	ardiae/pulmonery) TRISK of PE fibrinalytic
(	if fibrinolytic jivin - 60-90 min CPR.
	Late become a second to the second se



-Loc	ial i	4	Reg	اها	14		Ar	16	SH	he	Si	2								
Local																				
Def	Substan	ce w	hich n	evers	ible	ınh	ibits	ne	rve	Col	ndu	ction	r,d	irec	łly ·	o t	ssue	s ,n	on-	łох
	lockgen	eretic	on, pro	PSS	tion	<b>4</b> o	scill	stio	n o	f el	ech	ical	im	pul	ses.					
L,	cting of	Net	chan	nels	(p	rev	ent	de	pola	riz	atio	n).								
pherma.	Li	pid-s	oluble	e,Su	bst	lute	ed l	en	zer	e r	ing	+4	min	e (	am	ide	or é	ste	r)v	<b>ia</b>
	Es	ters	(1)	am	ino	este	rs (	in L	ive	T 01	r pl	esm	a c	holi	nes	rase	2).			
				Sh							Ľ									
				†SE				les	Dat	roen	nido	ben	Zoí	C 00	id	(PA	BA)	_	All	<b>e</b> 11
	A	nide	1 1	ma					•				-							-4
		<b>(2</b> i				act								caine nloroproc	a <mark>i</mark> ne		Amides Bupivaca Lidocain	aine		
				10	Š		.6	•						oca <mark>i</mark> ne tracaine			Ropivaci Etidocai			
Formula	lian . D	عمامه	برا اور	ولم		e,L	la.	<u> </u>		C			le .		Os.	100	riepįvac	ante		اما
	can be																		- 30	N GR
							_			•					JIAN	n pe	TEE	11/		
	→ 2g/								_		<b>20</b> 1	7	M	•						
vasocon	r (ICTOIS		Mhy?																	
				┢		cfe									uT '	to f	)Un	16 –	<b>→</b> 6	TOX
				┢		Λţ														
				H	1.	ceL													_	
			allou					•												
		$\mapsto$	not u	sed i	n:-	Fing	ers	,To	<b>62</b> */	Nos	e,E	<b>A</b> F	Lob	es ,	pei	is (	no co	later	als-	• isc
			1																	
Bupivac	zine (/	am ide																		
				+inf	iltre	tio	n D	ose			mg	•	7				50	) Kg	max	2mg/K
	esthesia: Use 0.5-0.7 to 5-hr duration, max								Щ	<b>3</b>	mg	/Ķ	<b>)</b> N	ith	ep:	•	-	50x 2 0.25% .	2= 100 2.5 r	mg mg/ml
Spinal and	vith epinephrine) esthesia: Use 0.5-0.75 duration, max dose 2		et,	Col	nce	ntra	tion	۱_	-	0.	2 <i>57</i> ,	1	ares	-			So ma	ximum r 100/2	mls for 2.5 = 40	
	ipivacaine less cardio upivacaine, same	otoxic than							L,	0.5			rec							<u> </u>
				Col	ntra	ind	icat	ed	Iv	4-	<b>C</b> C	cdi	oto	Kic	(H	per	łen	tior	12	411
Lidocai	ne(Am	ide)		inf	Hea	tion	do	se_		51	mg/	Ka								
Epidural anesthesia: u duration, max dose epipentrine)	use 1.5-2%, fast onset, 1- to 300 mg (500 mg with	2-hr									nj/		w	h e	ρi					
	se 1.5-2%, fast onset, 0.5- t se 100 mg use 4%, fast onset, 0.5- to 1 300 mg 5-0.5%, fast onset, 0.5-1 hr	to 1- 1-hr		Co	nce	ntc	atio	n (	2-		0		1	<b>y</b>						
• IV regional: Use 0.2! duration, max dose	-0.0%, rast onset, 0.5-1 hr 300 mg	40										L	2	<u>,</u>						
<b>→</b> Allery	(reso)		most	14 6	afze	rs -		DAG	<b>3</b> A_	Lik	e (	O.	Dat							
<b>—</b>		$\rightarrow$					_	****			_		1		_	T				T

	_ <b>L</b>	syste	Mic.						LvL	of a	lrug	,2°	to	abs	rpłi	on l	<b>TOM</b>	Lni	ection	n s
				<b> </b>	c N	S,RS	, cus	5	<b>.</b>											_
										dne	s,†	inni	tus	to	Seiz	ure	K c	NS/	cvs c	ااد
				-	IX:	-intr	4 - Li	pıa.												
Regio	naL	ange	sthe	sia (	(Spi	nal	,epi	idu	raL,	.Ca	udi	als)								
Deff_	→ Re	sions	۲,	Dri	yg .	direc	tly :	to s	pina	La	ord	or.	Neı	ve ·	to	OCA	ا وا	اعوار	K # &	E
			┢	alo	ne	or i	uth	ger	1614	L aı	rest	hes	ia.							
	0_0													rinf	ul i	mp	alse.	i to	highe	**
	→ Spi	nac:- idural																		
		udal															· Ne	rve	root	<b>ls</b> .
						aL					$\vdash$						ial			
Lul						ruda				<u>(2</u> )		F	1	Q			. 0	5	pinal	•
inse	rtion			it L	u-l	50	r L	3 - L	·u						Col	d				
site of	inter	ion		Suh	250	chne	ad.	<b>SOC</b>	ce				00;	du	14	21	) 9 9			
													Sp.			7				
cathe	eter u	se		No		Sins	le s	hot	<b>!)</b>				ye	25	(L	ons	ti	me	<b>)</b>	
							1							•						_
onset	of Act	ion				nin	ıtes						S	lo	ગ્લા					+
Nature	· · ·	Cart		Carre	ماد	ete	(a	n Ca	ru				60	n C	~		الن	1	me	D
(sensory,						otor							4	da	6		» M	ot	or	4
	,,,												Ľ							
Type	of			lny	Sh	MCY	be	Plou	Tie				Paid	n (	on	tro	Li	n c	leliv	e
	ery			Hei	ni	i, Kr	ee 1	repl	<b>QCM</b>	tn:				C	se	tio	n			
																			lion	_






## 6-Fliud management & Blood Transfusion Mg2+ HPO42-Sulphate- Essential principles. osmolarity: No. of osmoles of solute particle/volume (osmoles/L or milliosmole). osmobility:- No. of osmoles of solute particle/weight (osmoles/Kg). plasma osmolality \_\_\_\_\_\_ 2 (Na+k) + slucose + urea. Range: 275-299. the relative solute concentration of 2 solutions which are separated by To nicity\_ a selectively-permeable membrane (semi-permable membrane). isotonic: normal No movement. Hypotonic dilute, inside movement - swallon RBC. - Hypertonic: concentrated, outside movement -> shruken RBC. input:-oral, Enteral, IV. output\_\_sensible (measurable) : eaisly seen (urine GIT). \_\_ insensible (non-measurable):-not easy Quantify (Sweat, vapor). maintainance: Surgery requirement flinds. Rule of 4/2/1 or K9+komL/h deficit:- Before Surgery (fasting) Surgical flind Loss \_\_min. tissue trauma (Herniorrhops): 0-2 ml/Kg/h modrate tissue . (cholecystomy) = 4-6 mL/Kg/h -sever tissue " (bowel resection):-8-lo mL/Kg/h Adjust blood Loss \_\_\_\_\_ 1 ml of Blood Coss \_\_\_\_ 1 calloid (Blood product) \_ Lap pods: loo - 150 ml \_ 3 crystalloid (normal saline) Allowable Blood Loss \_ EBV x (Hi-HE) Final Hb (comest acceptable) \_\_small pads:-10 Estimated Blood volume = Kgx Avarge Blood volume (ml/Kg) Normal HeT \_\_\_ M:-42-52%


example Joky man - EBV = Jox +5 = 5250 ml.

LABL = 5250 x 20% = 1050mL


	Fluid Loss 1:3, tHydros Solution of w Balanced (Rin Cactate (Hartm	ger's L	relect actate	rolyt	les. Hy	n into	ersti nic (	tial. (DSW)	).			
	Solution of w Balanced (Rin	ger's L	relect actate	rolyt	les. Hy	n into	ersti nic (	tial. (DSW)	).			
	Solution of w Balanced (Rin	ger's L	relect actate	rolyt	les. Hy	poto	nic (	(DSW)				
						poto	nic (	(DSW)	).			
						pero	1	Dow	<b>'</b>	-	_	
1 Ringer's	Cactate (Hartm	4n's)_	\	1.+				1 1				
T Ringers	Cactate (Harim	4ns)_	<b>&gt; ^</b>		100.0		. /.					H
				1Q" ;-	[3] 1	nMo	L/L				-	-
			c									
			<b>\</b>	acte	te :-	29 1	mme	,L/L				L
			<b>L</b> →K	<b>+</b> _ 5	mm	oL/L						
						mmo						
			P									
				7 - C	1.1.1.	. 43	LQ _		,			
				SIVIOI	A			nosm/	4		••	
			<b>└</b>	<b>fobl</b> (	ems:	- Acc	uMu	lation	of K	Hy	perKa	len
							-					H
Normal Sali	ne (0.9%)	Nacl	و9 -: ا	/L		_						
		Na:	- 15h	mm	ioL/L							
		٠: اع	- 154 m	mol	1/1							
		OSme	placity	= 3	n Ba	rosm	h (	isotor	nic)			
		PH:-	_									
	-	Pri .	em » H		-hl-	Fo 674		a olak	lia a	معطمة		
	-	Probi	emsn	y Per	Cilibi	4EM	. 00	METHO	iic a	CICION	S . IV	O
		Li	kely u	VITA	rena	il in	SUFF	icienc	<b>y</b> -			H
							-				-	H
L_13 Others_	Hypertonic	(37.)	<b>→                                    </b>	lacL	. <del>:-</del> 3e	2 gm						
			0	smo	lality	1:10	027					
			<b>⊢</b> →P	y :_ L	1.5	to 7	<i>f</i>					
			L	YP01	natre	emia.						
	Half normal	soline		lack	. 7	1 me	9/L					
		7,,,,,		Cnto	لخلما	y -	KLI					Т
				31710		emic	154		_		_	
			<b>├</b> ┩ᡛ	yper	natr	EM/C	-				1.	
	4 10 4							cere	breL	ede	MQ.	-
	→84% Bican	rbong	te _	_	7	idos				_		L
	mannitoL	20%				eden			_			
				oulm	ONG	ry e	der	na.				L
			1 1		🔽			1 1				


colloids							se		+
	- Harmful	in copille	z Leak	ye (se	psis, A	RDS).			
	Exerts an o	smotic pr	essure in	blood	, Causi	ng Flu	id to rei	mein (†	Iv
	Categories_	Natu	iral (Al	bumin	١. ا				
		Artif	icial (ge	elatine	s, dextr	an & 1	ies).		
1									
Albumin_	-+ 1/2:-1	.66							
	Stay in S		ular se	sce UI	less co	موالوه	Perma	bility i	i abi
	5% solu								
	-expands								<b>~</b> )
	SE Vo	lugge		L SON	т	-161 AE	161/cc	raficito	· · / ·
	SE V	Julie of	/E1 1040						
	T PE	ver (py	iggens)						
	<b>□ □ □ 0</b> €	fects in	haemost	asis .					
2				1					
<b>→</b> Dextran	High	MW Po	ysacch	aride .					-
		pes 4	M۱ - د	v Uo,	,000				
		<b>L</b> 3	6 :- Ml	) to,	000				
		in NS c	or D54	) (H	ypoton	ic).			
		anaphyl							
		Coggul	pethy						
		Coayul Renal	feliure						
		:- 20 ml							
	USec	l as anti	ASSES	ent in	otc. 4	ndema	ins Vas	ruler	
			ישינטי				hole blood		
Blood prod	acts Contra	أحلمناهن	unless	:44 inc	أدمامط	-Pa	cked Red Blood Cells	PR9c <sub>3</sub> >	
Dieod pied	contro	Indicated	uriless	11.3 100	ricareu		atelets yprecipitate		
purpose.	mainiam	organ Th	20214310	n.		·Fr	esh Frozen Plasma	0	
- purpose.	Normal	RL'HK'W	टावापु ,	U <sub>2</sub> , U	rine ou	TPUT, U	vell per	rusea e	XT
preperati	011 <b>54Ph</b> (	1112					- Collect 500 mL whole - Divert the first 40 mL	entillugation	
	- Heps	litis B&C		Туре	Naturally Occurring	Incidence	The 40 mL are used donor unit testing Blood is centrifuged	anc	n Constad Units
	HIV	182		A	Antibodies in Serum Anti-B	45%	separated into 3 par  ◆ Red Blood Cells  ◆ Plasma	Bag 1-REC Same	
	+/- <	MV		B AB (Universal	Anti-A	8% 4%	· ♦ Buffy coat		
compati	bility testin	g (AB	o,Rh)	recipient) O (Universal donor)	) Anti-A, anti-B	43%	to separate the plate		processed
check b	efore transf	usion :-					The red blood cell ar	d platelet components are le	uxoreduced
1)group		. Name	5)	unit	No.		Pose 4 - Bully Coal Planet		
2)	day u)ma	dical sec	ا ما المد					Lipse	






7 - presperat	ive Assessment	
<ul> <li>introduction</li> </ul>		
	co-morbidites - complication during	peri-op peroid.
Venue	elective:- pre-op clinic or ward	s (angsthesig clinic)
	emergency:- ED/word.	
Estabish	e repport.	
conduct of Asse	sment:-History/PE/investigations	Angesthetic plan.
		•
1 History		
profile Name	e/ge/Gender/weight(Dosege), Heigh	<b>+</b>
Type Type	cing History: affect cilia	GT
Smok	(ing History: affect cilia	Respiratory         RESS           Acthma         Neuralinals.           CPPD         SERD           OSA         4-plesoy           GERD         CSF           Artipistelet           Recent-URTU/ARTI         <-OV/TIA
L. Fasti	ng hours: prevent aspiration.	Coupt (solum - Denervation disease Hiatus Hemia - On dalysis - Intestinal obstruction. On dalysis
ROS (focused)		
	DM. HTW, thyroid, mesthesia gravis	
	Drug History (B-blocker, statins)	
	allegies: penicilin & muscle Rela	xant.
	Sugical History.	
prevous Angesthes	sia previous difficult airway.	<ul> <li>Previous anesthesia</li> <li>Type of anesthesia</li> <li>Complications: difficult airway</li> </ul>
	previous airway surgery/burn.	management/delayed emergence / PONV)-Post of Mule & van 1/2 • Family hx. (malignant hyperlkimia/collen apne
	Snoring/obstructed breating	Family hx. (Mailynant Appetitimaly Collect april
	1.	
2 physical Examin		
Lieneral:-apperan	ce, obesity, mainutrition, pregrency, Head	l & neck.
Vitals: BP, HR, F	Check rate and rhythm Auscultate heart sounds	
cardiac exam.	ook for signs of resp. distress Respiratory rate Auscultate lung sounds	
Respiratory exam	Mental status	
neuro exam.	Gross motor/ gross sensory	
3 Airulau avasain	de a	
3 Airway examin		igh habing Illugaria cirle
incorton ca . cicus	e any possible difficulty in ventilation &	musen events ducine
Ongether:	y & Respiratory events are the most co c:- sore throat & dental dampe).	PININGI EVENIS QUITING
Undestresia (M	.: JOI E INIOUT & CEITIGE CHITYS).	







0		
D	- intrave	nous Anesthetics
	introduction	
Ī		Local infiltration: Nerve ending.
T		Single nerve block: all area supplied by the nerve
Г		- plexus black: group of nerves
		Neurexial block:- Resional (spinal/epidural).
L	signs & stages	(Reversable/controlled Loss of Consciousness).
'	sedation	mild CNS depression
		for surgical procedures, not requiring muscle Relaxation.
		Most aneithetics don't produce analgesia.
	Delicium_	Cortical motor depression - excited state.
		Cortical motor depression - excited state.  avoided with rapidly acting potent anesthetics.
L	Surgical At	nesthesia Subdivided into stages (9 muscle Relaxation).  Final stage No muscle tone
		final stage No muscle tone
L	L- Deep Anes	thesia & Respiratory paralysis not desirable Hypotension apnea + SE.
	•	Hypotension apnea + SE.
1		
Ļ	Traid of (Balan	nced) general AnasthasiaAnasthatic (Hypnosis):-unconsciousnas
		Analgesia: pain killer (opoids).
		Amnesia:- No Recall (Bezodiazepine
-		± muscle Relexation & Lautonomic Re
	Basic Pharm	acology principles
H	pharmacokine	tics:-How the body processes the drugs (ADME)
	- Administra	tion, mostly anesthetic by IV or inheled
		Sometimes IM
H	Metabolism	
		circulation - tractabolism by Liver (1 Bioavailability).
┢		L. IV drugs - No Cirst pass metabolism _ 100% Biographable - Lodose nee
┨		-through Liver, Kidney & Lungs.
$\blacksquare$	advantage connectation and filestation aris.	Zero-order:-metabolized at fixed rate, regardless of concentration.
$\vdash$	The codes desiration for the code of the c	- first-order mast drygs.
-		Rate of metabolism is proportineal to concentration.


	Distribu	ction:	- Syste	mic ci	cula	ion t	o ta	net c	organs	(Brein)			
	Pto:	lein l	ound	Li	ecti.	e (fr	ee p	ortion		ive).			
											centration		
	- va	10,000								rophilic			
	ارم	al .·l.	1	D (							urays.		
		STEIDU	171011	-tper							100 P	asma	MG Muscle
	11									organs		VRG	
	n the B									trubition			Tat FG
	the B									y ocean		0.1 1.0 Time (min)	10 100
10 min		iakne	SS.	Co	<b>unit</b> n	ue to	ske	up d	lay fa	m Bloc	ad.		
pha	macody	MAMic	:5										
<u> </u>	potency	:- dose	of dr	yg regu	red	o achi	eve	a the	repeut	ic effec	<del>.t</del> .		
	Efficacy	:- Ma	x. eff	ect ac	hieval	le wi	H H	he dr	ug.				
	Toxicity									on occu			
											to there	peutic	effect.
								9					
• Iv	doues												
1000	s diags	P. 9.a	J.,,,	0	. ا		<b>n</b>		0				
use	<sup>3</sup>   →	o in	auce	<b>A</b> MO	amta	n Gi	7 (1)	OP.	- 10017	1			
	<b>├</b> →	10	seda	rion		1							
				lures	outsi	de o	p-Ro	om.					
	_ <b> i</b>	n the	ICI	<b>y</b> .									
<b>⊢</b> Mol	A	poten	tiatio	n of G	ABA	Recep	tors	افرسم	nhibitoy	y neu	rons.		
								<u>_</u> †	cL flu	r pro	rons. motes hy	erpoleri.	zetion.
		nhebi	kng	NMDA	Rece	ptors	(Ket	emine	:) :-ex	itatory	neuron .		
				r acti									
am	puls (	one	use)	. Vial	s (n	uHi-	use)						
1 pro	anafal .	- MAC	1	man (	red	الممنا	وزاره	<b>Ω</b>		100	1		
	luction						1,10			166	PROPOFOL 40/		
4 7	uction	COSE	4.9	_ Z.5W	9/19						200 mg/20 mL (10 mg/mL) CONTAINS BENZYL ALCOHOL		
1/.	pre-p	repar	.eg —	> 10 M	9/m	<b>-</b>					in Norther 12 mg, beer of hydrodic Sonia, styli- teurs. Desert conting SMART MICH, DOING OR		
	A:- GAB										-		
	eł:- <mark>3</mark> -												
Con	tains:-	l7. eg	g leci	hin en	nulsi	naly	cerol	. K Sq	ybean	oil (Re	levant t	o pt all	ergies to
	egg whi	łe, n	ot co	ntrain	dicat	ed w	ith e	99 9	llergy	)			
L_adn	ninistrati	ion :-	only ]	CV (†	Lipid	Solubl	e).	-0	00				
	- 2-8							min					
7			,										


special formulation can support bacterial growth: 6h discharge.  pain on intection: +1% Lidocaine.  print of intection: +1% Lidocaine.  prevent PONV.  SE cvs & RS depressant: Hypotention, apnea, bradycardia.  18P, 1 contractility, 15VR, 1 preload: 1 symphatic tone & direct Vascular SM et Avoid in hemodynamic unstable pt.  Barbiturates thio-barbiturates: methohexital.  indiction close: 3-5 mg/kg.  each vial containas (sooms) powder of STP: + normal saline (20 ml).  2.5% soultion (25 mg/ml), Hishly alkaline (pH=10): cause burn.  onset: 30-60 sec, arm_Brain circulation time.  NOA: Enhance CABAA receptor transmission.  elimination: Hepalic metabolic rate of 02 (CMRO2)  lintracranial pressure  contraindication: pt. with porphysia (tporphysia formation = Meute crisis).  pregrancy & Lactation (narrow safety margin).  3 Etomidate  induction close: 0.2-0.3 mg/kg (potent).	excertio	n:- <mark>By</mark> 1	Kidney	(Rapid	hepa	ic meh	ebolis	m)						
pain on indection: +1% Lidocaine.  antipruritic & antiemetic properties  prevent PONV.  \$E cus & Rs depressant: Hypotention, apnea. bradycardia.  \$BP, & contractility, & svR, & prelead: Lymphatic tone & direct Vascular SM et Avoid in hemodynamic unstable pt.  2 Barbiturates  thio-barbiturates: methohexital.  indiction dose: 3-5 mg/kg.  each viel containas (Soom) powder of STP: + thormal saline (20 ml.).  2.5% southion (25 mg/ml.) Highly alkaline (pHolo): Cause burn.  Onset: 30-60 sec, arm. Brain circulation time.  Non: Enhance CABBa receptor transmission.  elimination: Hepstic metabolic rate of 02 (CMRO2)  torebral metabolic rate of 02 (CMRO2)  torebral metabolic rate of 02 (CMRO2)  protective effect at neurosa  contraindication: pt. with porphyria (1 porphyria formation = Acute crisis).  3 Etomidate  induction dose: 0.2 - 0.3 mg/kg (potent).  2 mg/mL Solution.  Non: Endos to CABBa Receptor.  Special pain on indection: Lidocaine.  tomadynamic stability (HR): Don't cause vasodistion or myocardial depression  Hemodynamic stability (HR): Don't cause vasodistion or myocardial depression  Contraindication = Sepsis	Special_	forn	nulation	Can Su	pport b	acteria	ورو	wth:	- Sh	di	charg	e		
antipruritic & antiemetic properties Used in TIVA (Total IV anesthesis)  SE														
Description of the property of		anti	pruritic	& antic	emetic	Proper	ties		Used	in TI	VA (T	otal :	[V and	esthesia
DE _ cus & Rs depressant :- Hypotention , apnea , bradycardia.    JBP , Lontractility , Lsvr. Lprelead :- Lsymphatic tone & direct Vascular SM et														
Barbituratesthio-barbiturates: thiopental.    Barbituratesthio-barbiturates: thiopental.   Day-barbiturates: methodexital.   Day-barbitu	SF J	*vc &	RC de	oressen-	Huz	atenti	an .	- 1	•					
Barbiturates		RP Ic	antrod	1:10 10	1/0 Ja		le				ر. ال	oct w	Seedle	الم الاي
Barbiturates		100,00	home	1,3,0		della	1	JINPI	41,6	one i	* COLU		JEGIGI	The Cla
indiction dose: 3-5 mg/kg.  each viel containa (Sooms) powder of STP: + thormal saline (20 mL).  2.5% soultion (25 mg/mL). Highly alkaline (pH alo): - cause burn.  Onset: 30-60 sec, arm_Brain circulation time.  MoR: Enhance CABRA receptor transmission.  elimination: Hepatic metabolic rate of 02 (CMRO2)  I crebral Blood flow (CBF).  protective effect at neurose  contraindication: pt. with porphyria (Tporphyrin formation - Acute crisis).  prestancy & Lactation (narrow safety margin).  Etomidate  induction dose: 0.2 - 0.3 mg/kg (potent).  2 mg/mL solution.  40A: Binds to CABRA Receptor.  Special pain on inlection: Lidocaine.  LCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure)  Hemodynamic stability (IHR): Don't cause vasodiation or myocardial depotence.  TPONV  LII-B-Hyroxlase (production of steroids) accremal suppression (u-8h).  Contraindication - Sepsis	<b>&gt;'</b>	3 4 9 1 9 11	n ueirie	y in the	L WII	214DIE	<b>P</b> 1.							
indiction dose: 3-5 mg/kg.  each vial containancy (sooms) powder of STP:- thormal saline (20 ml).  2.5% soultion (25 mg/mL), Highly alkaline (pH=10):- cause burn.  Onset: 3-60 sec, arm_Brain circulation time.  Map: Enhance CABBA receptor transmission.  elimination:- Hepstic metabolic rate of 02 (CMR02)  I crebral Blood Flow (CBF).  protective effect at neurose  contraindication:- pt. with porphyria (Tporphyrin formation - Acute crisis).  pregrancy & Lactation (narrow safety margin).  Etomiclate  induction dose:- 0.2 - 0.3 mg/kg (potent).  20mm  Alah:- Binds to CABBA Receptor.  Special pain on intection: Lidocaine.  I CMR02, CBF & TCP while maintain good CPP (crebral prefusion pressure)  Hemodynamic stability (HR):- Don't cause vasodiation or myocardial depression  SETONV  LII-B-Hyroxlase (production of steroids) addrenal suppression (k-8h).  Contraindication - Sepsis	T P1:1	calae	- 11	. 1	-	laa l'	١	1	1					
indiction dose:- 3-5 mg/Kg.  Peach Viel Containab (Sooms) powder of STP:- thormal saline (20 ml).  2.5% Soultion (25 mg/ml). Highly alkaline (pH=10):- Cause burn.  Onset:- 30-60 sec. arm_Brain circulation time.  MoA:- Enhance CABAR receptor transmission.  Plimination:- He patic metabolic rate of 02 (CMRO2)  Intracrantal pressure  Contraindication:- pt. with porphyria (Tporphyria formation - Acute crisis).  Pregrancy & Lactation (namou safety margin).  Etomicate  Induction dose:- 0-2-0.3 mg/Kg (potent).  20 mg/ml Solution.  MaA:- Binds to CABAR Receptor.  Special pain on intection: Lidocaine.  Hemodynamic stability (IMR):- Don't cause vasodilation or myocardial depicts of the contraindication - Sepsis	DALPIT	urates												
-each viel containas (Sooms) powder of STP:- thormal saline (20 ml).  2.5% Soultion (25 mg/ml), Highly alkaline (pHalo):- Cause burn.  Onset:- 30-60 sec, arm_Brain circulation time.  MoA:- Enhance CABAn receptor transmission.  elimination:- Hepatic metabolic rate of O2 (CMRO2)			, ·	•		es :- n	1eth	ohe)	cital.					
2.5% soultion (25 mg/ml). Highly alkaline (pHalo):- cause burn.  Onset:- 30-60 sec, arm_Brain circulation time.  MoA:- Enhance CABAn receptor transmission.  elimination:- Hepatic metabolic rate of 02 (CMRO2)  Lintracranial pressure  contraindication:- pt. with porphyria (Tporphyria formation - Acute crisis).  pressure  contraindication dose:- 0.2 - 0.3 mg/kg (potent).  2mg/ml solution.  Man:- Binds to CABAn Receptor.  Special pain on intection: Lidocaine.  LCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure).  Hemodynamic stability (LHR):- Don't cause vasodiation or myocardial depression (u-8h).  Contraindication - Sepsis	•				l -									
onset: 30-60 sec, arm_Brain circulation time.  MoR: Enhance CABRA receptor transmission.  elimination: Hepatic metabolism.  special trebral metabolic rate of 02 (CMRO2)  trebral Blood Flow (CBF).  protective effect at neurosa  contraindication: pt. with porphyria (Tporphyrin formation - Acute crisis).  prestrancy & Lactation (Narrow safety margin).  Etomialate  induction dose: 0.2.03 mg/kg (potent).  2 mg/mL Solution.  MoA: Binds to CABRA Receptor.  special pain on intection: Lidocaine.  tCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure)  Hemadynamic stability (LHR): Don't cause vasodilation or myocurdus depression  LIII-P Hyrox ase (production of steroids) and renal suppression (u-8h).  Contraindication - Sepsis													/	1
Onset: 30-60 sec, arm_Brain circulation time.  HoA:- Enhance CABAR receptor transmission.  elimination:- Hepstic metabolism.  special trebral metabolic rate of 02 (CMRO2)  trebral Blood Flow (CBF).  protective effect at neurosa  contraindication:- pt. with porphyria (Tporphyrin formation - Acute crisis).  prestancy & Lactation (Narrow safety margin).  Etomidate  induction dose:- 0.2 - 0.3 mg/kg (potent).  2 mg/mL Solution.  HoA:- Binds to CABAR Receptor.  special pain on intection: Lidocaine.  tCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure)  Hemodynamic stability (LHR):- Don't cause vasodilation or myocurdual depotention of steroids)  Contraindication - Sepsis	<b>→ 2.5%</b> s	pultion	(25 mg	/mL)	Hish	y alka	line	(PH	ء(دا <b>د</b>	Caus	e bu	m.		
MoR:- Enhance CABRA receptor transmission.  - elimination:- Nepatic metabolism.  - special - crebral metabolic rate of 02 (CMR02)  - crebral Blood Flow (CBF).  - intracranial pressure  - contraindication:- pt. with porphyria (Tporphyria formation - Acute crisis).  - pressure  - induction dose:- 0-2 - 0.3 mg/kg (potent).  - 2 mg/mL Solution.  - Man:- Binds to CABRA Receptor.  - special - pain on intection: Lidocaine.  - tCMR02, CBF & ICP while maintain good CPP (crebral prefusion pressure)  - Hemodynamic stability (HR):- Don't cause vasodilation or myocardial depotence of the contraindication - sepsis													Thic 500 for	mg powder injection.
elimination:-Hepsic metabolic rate of 02 (CMRO2)  - Crebral metabolic rate of 02 (CMRO2)  - Crebral Blood Flow (CBF).  - Intracranial pressure  - Contraindication:- pt. with porphyria (Tporphyrin formation - Acute crisis).  - pressure & Lactation (Namow safety margin).  Binduction dose:- 0.2 - 0.3 mg/kg (potent).  - 2 mg/mL Solution.  - Man:- Binds to CABBA Receptor.  - Special pain on infection: Lidocaine.  - LCMRO2, CBF &ICP while maintain good CPP (crebral prefusion pressure themodynamic stability (LHR):- Don't cause vasodilation or myocardial depotence.  - TPONV  - 111-B-Hyroxlase (production of steroids) - acirenal suppression (k-8h).  - Contraindication - Sepsis	MoA:- E	nhance	CABA	rece	ptor t	Fransm	issic	n.					Each Th Thi Sodia	opental Sodium (as opental Sodium and opental Sodiu
Special of crebral metabolic rate of 02 (CMRO2)  Intracranial pressure  Contraindication:  pt. with porphyria (Tporphyria formation - Acute crisis).  presrancy & Lactation (narrow safety maryin).  Etomidate  induction dose: 0.2 - 0.3 mg/Ky (potent).  2 mg/mL Solution.  Man: Binds to CABAA Receptor.  Special pain on injection: Lidocaine.  ICMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure Hemodynamic stability (LHR):- Don't cause vasodilation or myocardial depotence of the contraindication - Sepsis													6	ynimedes
Contraindication:  pt. with porphyria (Tporphyrin formation — Acute crisis).  prestancy & Lactation (Namou safety margin).  Etomidate  induction dose: 0.2 - 0.3 mg/Kg (potent).  2 mg/mL Solution.  Alah: Binds to CABAR Receptor.  Special pain on injection: Lidocaine.  LCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure Hemodynamic stability (JHR): Don't cause vasodilation or myocardial depotence of the contraindication — Sepsis							CMI	20-1						
Contraindication:  pt. with perphysia (Tperphysia Formation - Acute crisis).  pregrancy & Lactation (Name Safety margin).  Etomidate  induction dose = 0.2 - 0.3 mg/kg (potent).  2 mg/mL Solution.  Aloh: Binds to CABAR Receptor.  Special pain on intection: Lidocaine.  I CARO2, CBF & ICP while maintain good CPP (crebral prefusion pressure).  Hemodynamic stability (IHR): Don't cause vasodilation or myocardial depotency of the couse vasodilation of the couse vasodilation or myocardial depotency of the couse vasodilation or myocardial depotency of the couse vasodilation of the cou								1027	٦.	Drole	ورياء	elfa	L .1 .	
Contraindication:  pt. with porphyria (Tporphyrin formation — Acute crisis).  prestancy & Lactation (Namou safety margin).  Etomiolate  induction dose = 0.2 - 0.3 mg/kg (potent).  2 mg/mL Solution.  Alon: Binds to CABAD Receptor.  Special — pain on injection: Lidocaine.  LCARO2, CBF & ICP while maintain good CPP (crebral prefusion pressure themodynamic stability (LHR):-Don't cause vasodilation or myocardial depotency of the contraindication — Sepsis							•		┌	Plore		CITEL		ILE MINOS OF
prestancy & Lactation (name safety margin).  Etomiolate  induction dose = 0.2 - 0.3 mg/Ks (potent).  2 mg/mL Solution.  Mon: Binds to CABAR Receptor.  Special pain on injection: Lidocaine.  LCMRO2, CBF & ICP while maintain good CPP (crebral prefusion pressure themodynamic stability (LHR): Don't cause vasodilation or myocardial depotence to the contraint of the							١.				_	1.		
induction dose: 0-2-0.3 mg/kg (potent).  2 mg/ml Solution.  4 Moh: Binds to CABAD Receptor.  Special pain on injection: Lidocaine.  LCMROz, CBF & ICP while maintain good CPP (crebral prefusion pressure).  Hemodynamic stability (1 HR): Don't cause vasodiation or myocardial depotency.  SE TPONV  LII-B-Hyroxlase (production of steroids) advenal suppression (u-8h).  Contraindication Sepsis	Contrain	Xi CQ†iOT	<b>'┼─→ [°</b>	i. With	porphy	ria (Tp	otbp	rin t	orm41		→ Acu	te cr	isis).	
induction dose: 0.2 - 0.3 mg/kg (potent).  2 mg/mL Solution.  4 Moh: Binds to CABAR Receptor.  Special pain on injection: Lidocaine.  LCMRO2, CBF &ICP while maintain good CPP (crebral prefusion pressure).  Hemodynamic stability (1HR): Don't cause vasodilation or myocardial depotent prefusion of steroids).  20 mg/mL  10 mg/mL  20 mg/ml  10 mg/ml	2 (1	, ,	— <b>P</b> P	restang	y a i	_actati	on	Nen	و لاه	arety	wel	jin).		
20mg prince   20													-	
Mon: Binds to CABAR Receptor.  Special pain on injection: Lidocaine.  LCMRO2, CBF &ICP while maintain good CPP (crebral prefusion pressure)  Hemodynamic stability (LHR): Don't cause vasodilation or myocardial deposite.  SE TPONV  LII-B Hyroxlase (production of steroids) adrenal suppression (u-8h).  Contraindication Sepsis	-induction	on dose	2 - 0-2	- 0.3 m	1K2 (1	potent)	<b>).</b>						-	Etomida
Hon: Binds to CABAD Receptor.  Special pain on intection: Lidocaine.  LCMROz, CBF & ICP while maintain good CPP (crebral prefusion pressure)  Hemodynamic stability (1HR): Don't cause vasodiation or myocardial deposite.  SE TPONV  LII-B-Hyroxlase (production of steroids) adrenal suppression (u-8h).  Contraindication Sepsis													-	20 mg per 1
LAROZ, CBF &ICP while maintain good CPP (crebral prefusion pressure Hemodynamic stability (LHR): Don't cause vasodilation or myocardial deposite TPONV  LII-B-Hyroxlase (production of steroids) — adrenal suppression (u-8h).  Contraindication — Sepsis	→ HoA:- B	inds to	CABA	A Rece	ptor.									For Intraven 10 mL Single-D
LAROZ, CBF &ICP while maintain good CPP (crebral prefusion pressure Hemodynamic stability (LHR): Don't cause vasodilation or myocardial deposite TPONV  LII-B-Hyroxlase (production of steroids) — adrenal suppression (u-8h).  Contraindication — Sepsis						aine.				->65	eizur	eş		
Hemodynamic stability (LHR): Don't cause vasodiation or myocardial deposits  TPONV  LIII-B-Hyroxlase (production of steroids)—adrenal suppression (u-8h).  Contraindication——sepsis		Lica	uro,	CBF &I	CP wh	ile m	inte	n joe	d CF	P (cr	ebral	prefu	sion	pressur
TPONV		LHen	aduner	nic sta	bilide (	THE):-	Den'	CEM	se va	sodile	ion o	r Muo	cardia	L desc
					7									
Contraindication sepsis	•	-		ا محما	.al:	ما داء-	ا الم		<u></u>	ad e	100	esio =	(L-6	N
			<b>-</b>	*		OF SIEL	old S,		40161	Jac 3	rppre	110166	(u-8	11).
Steroid use	Contrai	naiCatio	<sup>pn</sup> —											
				Steroi	d use									

ſ	1.	1/ 1																
Į			ami		-					-							· ·	
		Dos	و	١١	/ :- <mark>:</mark>	L-2	ms/	K9.										Dr. and
ľ				T	u I				(sevi	eral	Rout	es)						KETAMINE HCI
t				-> 10	<b>VI</b> :- <b>V</b>	-0	ייקיי	<b>y</b> ,										500 mg/10 mL* (50 mg/mL)
ļ	_	Mol	):- <mark>N</mark>	MD	A QI	ntego	bnism	ı (N.	-Mei	hyL-	D-4	spar	late)	)				For Intramuscular of Slew Intravenous USE Sterie
L		Spec	ific	Ш,	An	ela es	sic el	Yect.	B	ocki	11 D	ein S	knel	c el s	pinal	cord.		and Multi-Dose
I				Т		U			J.							11	-1	01
ł										76.821	DCiQTI	7	ne s	7nec	DETW	een th	SISM (	2 Limbic
ı				Н	Stir	nula	le sy	mphe	tic N	ervo	ws Sy	stem	<b>!</b>					
ı				L.	18	espi	retory	, de	pres	ian	(Br	nch	واناه	tion)				
I						•			•									
ł							LMR				_							
1									<u> </u>									
		SEL												s pons	ve t	Sen	ory is	nout.
ſ											. 1.	D	Par			4	pine.	
ł														-30	enzq	oeze	pine.	
L	$\rightarrow$	Con	train	dica	tion	) :- 🗲	pace-	. 066	uping	CN	is Le	Sion	+					
1							<b>'</b>											
ı	5	No	<b>V G</b> • 6	ام ا		٠.]:_	<u> </u>		dex)	1								
							e (P	iece	aex,	<b>'</b> -								
ŀ	->	Дof	1:- 🗸	2 9	soni	54												
			:- 2															
Ī	_	-			1.	•		4	IV	/1								
ł	-	POSI							ဌ/Kု		min							
ı				→ in	fusi	on :-	0.2 -	0.7	my/1	<b>9</b>							_	
L		eff	ects:	. Se	deli	ve .	anele	esic	.Symi	octhe	Julia	. a h	Xialy	lie (	<b>LResp</b>	icho	ı dep	ression).
Ī		20.				la P.			ntuba				U			9		
ł	-	mai	CGT/O	n :- <u>(</u>	War	e Fi	DELO	TIE I	ntu De	non.								
ŀ	_			•														
	6	Be	<b>N2</b> 00	iaz	epe	ns ⊶	mi da	zolan	n (sho	d).	Diaz	:e 041	w (La	ne).	0147	Pem	Linter	mediate).
Ī		aM.	1.	20V2	. 1. 1			1				1.	1.	0		/ AL	1	
1	$\rightarrow$	CHE	<b>-75:-</b>	AUX	Plyt	ا4, ع	mnes	TIC,S	<b>ea</b> 511	AE'L	iy pne	TIC,	anne	ONV	ISONT	(700	T Un	lgesic).
4	-	MoF	I:- <mark>Bi</mark>	nds :	to (	ABA	la at	· diff	rent	site	۲							
ı		Th	3	HR.														
					_1_	\			٠	l					1.	1		
1	<b>-</b>	روم	e (n	1199	ZOIG	m) L	→PI	e-m	ea (Cq	tion :	- 0.01	( - D -	05 17	7/19	(1-2	mg).		
4						L	in	duct	ion :-	0.1-	0.2	m,9/	19		Rapid			
ı		use	S:- 🔼	em é	dice	tion	1.50	letia	n &	on Xi	alyci	: Le	iare	GA.	High li	oid solubility		
		00		1 0	CD	C) 10	2				0				Rapid (		ccumulation c	luring prolonged infus
-	-	>L:-	mile	T K	2 4	CVS	9 1	pper		3	repl	EX O	repre	SSion	Analge	sic effect	lar and servi	ton, doprovise
	<b>-</b>	Ant	dote	<u> </u>	lum	aze	niL (	Comp	elili	ve q	ntesa	nist.	<b>).</b>		iviinima	etic effects	iar and respira	itory depression
			CV	s	RS	CNS	S	Drug	Speed of Induction Recovery	and Pain on	injection D	lirium PONV	analgesia			n on injection		The second
T					Ventilation			Thiopental	Fast <1 minute Accumulation or		No	- 0	- 6	nalgesia l			ergence pheni	omena
+		Barbiturate	+ -	-	Mechanical			Etumidate	giving slow reco	6	res .	. +	antanalgesic f			eraction with o	other agents ertent intra-an	torial injection
4	Be	Proposol enzodiazepines	0		( )			Propofel	Fairly fast reco Fast onset	6	Yes		0			ic effects	ertent mua-ar	tenai injection
		Etomidate	0 0	-/0	-			Ketamine	Very fast recov Slow onset Slower than of	1	No	++ ++	++				e /No hyperse	nsitivity reactions
_		Kelamine	++ 0	++	(+/-/0)	+++ +	+++	Midvelon	Slower than of	. ,	No	- 0	0					

## 9 - Inhalational Anesthetics · introduction vapor - mixed gas + Lighted, can go back to Lighted in thressure, All Agents. gas:- No, Oz, medical air, can't go back to Liquid. inhalation drugs: Liquids with tendency to vaponise dilivered through RS, usually halogenated hydrocarbons or eitheirs, via a vaporizer. critical temp: temp above which a substance can't be Liguified (only gas), Below this Liquid co-exist with their gas form (Vapor). water 374c. saturated vapour pressure (SVP) - pressure exerted by vapour phase of a substance when in equilibrum with the Liquid phase, determines the effect of grents vaporizer Pharmacokinetics uptake & distribution depth of GA depend on partial pressure (gas fraction) exerted to brain. Pr > PA > Pa > Pb - equilibrium - gas analyzer A=B partition Coefficents:-Relative solubilities of an air/Blood/tissue - Ratio of concentration of the anesthetic vapour in each of two phases of steady state Steady state: equal partial pressure in the two phases. in Blood -> some will become Liguid (ineffective) -> + Gas Blood: Gas partition coefficient (26/3) \_onset & offset -compares conc. of undissolved vapor in Blood to undissolved vapor in alvertiat equal pressure.

Diffren	artition coeffice of conanti	ration of u	ndissolve	d Vapor	from brain	to blood
Relote	d to Lipid solu	ebility & pe	tency (A	#C :- 1m	ac = Lpotence	<u>, ).                                     </u>
					A	gent MAC (%)
minimum	Alveolar cond	centration	(MAC	)	Desflurane	6.6
l bett	Partial pressure	of one in	al akick	بيهم النب	Sevoflurane	2.0
	with conc. is		no al	1 N	Isoflurane	1.1
						0.75 highest po
	MAC that previ					Sow ansettal
	Response to					104 least pote
	= ED50: Effective					
provide	e standart way o	f estimating	2 anesth	etic depth	& Compering	gents.
values	0.3_o.k (M	AC - awake	):-awak	ening From	m anesthesia (	als of others).
	1.3 (ED95):	bluntine	of Reson	nse in 9	5% of at	
	1.5 (MACBA	DI-U	and at a	Ironam:	researce L	surgical elica
مرادم	la contra		or at	- renery ic	, response to	Jan Jan Silin
Mation	ale easily m		COTIC.		PHYSIOLOGIC FACTORS	C & PHARMACOLO
	(A) = (E				Increase in MAC:-  - Hyperthermia Up to 42 - Hypernatraemia	Decrease in MAC:  - Hypothermia & Hyporther - Hypothermia & Hyporther - Hypothermia (available) - Cate cholamine (available)
	invariant with		F Noxious	Stimuli.	Drug induced elevation CNS catecholamine sto     Chronic alcohol abuse chronic opioid abuse     Increases in ambient o	nof increasing age (6% decrease)  Proper size in Property in Pr
	Jindividual va	riability.			(experimental)  Cyclosporine  Excess pheomelanin production(red hair)	organism drugs - Guesta Green drugs - Guesta Green drugs -
	don4 alter by	(sex, Height	weight,	luration)	When Motors and supplies the supplies of the s	
	doses of anaest				1840 1877 1840)  James Sergers, and the sergers behaviors with the serger series behaviors.	
					- Company of the Comp	
Inhalation	al asents					
	Utraumatic > 0	المحمد أماذا	ا ما	- 1-0-	الداداء مرد	.
					والمعالمة المعالمة	<b>!•</b>
	Difficult IV ac					
	Spontaneous ve					
	Titration of de					thotics
	Bronchodilation	(Asthma	, COPD).	Met	abolism of inha	led anesthetics
	Brief angesthe					metabolized
					Halothane	20
Disedy_	Bad Smell				Sevoflurane	2-5
		(0.001			Enflurane	0.2
	Airway inritatio				Isoflurane Desflurane	0.02
	Excitation plan				Nitrous Oxide	0.004
<b></b>	cardiac & resp	piretory de	pression			
	Theatre pollution	on (Leakir				





	0651	etr	ic	effe	eds		1 -	<b>→</b> [	5)											
	Dose	4						_			lood	Flow	(16	isK	past	pertu	em b	lee	din	رړ
-	May					_								l '		<u> </u>				
	Rapio				_   <u></u>				h the	fet	us (	causi	ng R	s de	press	ion)				
7	Xer	ากท																		
	None			Onn.	-DuD(	et.	cha	<b>Mica</b>	II. is	ert.	IDA	MV								
	No								<b>9</b> "	<u> </u>	410									
	†Cos					AICT	<b>-</b> -													
•				ТО	use.															
•	Hac:						,													
	Have							•												
	Mini																			
~	seen	ns 1	iot	to +	rigge	r n	1ali)	nent	t hy	pert	hern	nia.								
					- 45															
	Malj	gna	nt	Hype	erthe	m	la l													
_	Deft:	. Ge	nitic	(AD)	Hyp	erm	etab	olic (	dise	ase	to	inhal	alion	0	Suci	inyl	choli	ne	exc	zepł
_ <u>`</u>	featu	ces_	<mark></mark>	ene (	or R	yan	odin	e (R	yr1)	in c	hron	nosom	e 19	(†ca	rela	se f	Mot	SR	)	
·				ducti																
				o]. a					•		<u>.</u>									
				dult																
	noth.	, AL	cial		1		_1:	ab:6	:1:0	1	lr.	ania	$\perp$	ucto	inad	me	(cla	Can	t Cer	4:
	patho	לדי	(	<b>y</b> T	10			f	4		LL.						00			L
					<b>→</b> '''	. 6	CHUI	7	Tre	THE	Figo!			.005		. 0	AT	2	2100	
	<b>-</b>	1	1.								maj		<u>L</u> acti	e ac	I GIOS :	5 4	116	;mp	•	
<b>→</b>	Tx:-	lant	Tole	ine s	sodiv	IM_	+ Su	ppor	tive	•		TABLE 8-4	6 Clinical pha	rmacology o	f inhalational	anesthetics.				
				W 1 1 1					+			Cardiovascul Blood pres Heart rate Systemic ov	lar ssure vascular resistance	Nitrous C N/C N/C N/C	ti N/C	ane Isoflura	ne Desfi	turane :	Sevoflurane	-
		Increased carbon- Increased oxygen Reduced mixed vo Metabolic acidosi	i metanousm Joside production consumption nous oxygen tension s	Hyperphosphatema Myoglobinemia	3	10 Pathogne	Malignant hy	perthermia	-			Respiratory Tidal volum Respirator Paco, Resting	me y rate	‡ N/C	##	<b>+</b>		‡	‡	-
		Cyanosis Motling Increased sympath Tachycardia	atic activity	Myoglobinaria	7. 2.	COa incr	rease by each breat	10	-			Cerebral Blood flow Intracrania Gerebral m Setzums	r al pressure netabolic rate	Ī	#	1	1	†† †	† ‡	Н
		Hypertension Arrhythmias Muscle damage		Hyperthermia Fever		5							ellar artzing blockade <sup>3</sup> od flow or filtration rate stput	† #	11	111 #	1	†	11	
		Muscle darauge Masseter spasm Generalized rigid Increased serum o Hyperkalemia Hypernatremia	y centine kinase	Swearing		٠	4 8	12	16			Hepatic Blood flow Metabolism*		11 + 0.004			্ ব	↓ ↓ 0.1%	‡ 5%	
												N/C, no change. Controlled venti Depolarizing bio	ilation. ockage is probably al	so prolonged by the	se agents, but this is	usually not clinicall	y significant.			
				and the		mia	natment and					Figure 29.5	S Ranking of clinic	cal properties of v			halothane, I =	isoflurane, S		
		IV	lalign	ant Hy	pertner	IIIId tre	eatiment and	diagnosis												
		Discontinue volat     help.	ile anesthetic and st	accinylcholine. Notify th	e sargeon. Call for	IIIId tre	Onical sussicio						ascular stability	D H	t V	orse	Better H D	s s		
		Discontinue volat     help.     Antidore     Mix dantrolene so     intravenously as s	ile anesthetic and su dum with sterile di con as possible.	necinylcholine. Notify the fistilled water, and admir SUDI	e sargeon. Call for		Clinical suspicio	on of Mil				Cardiova Respirato Ease of ti	ascular stability ory irritation itration ace	D H D H	1		D S S	S S H & S D	s	
		Discontinue volat help.     Mix dartrolene si intravenously as s     Administer board     Institute cooling is     Treat severe hipe	ile anesthetic and su edium/with sterile di non as possible. Donate for metabolic neasures (lavage, co rikalemia with deutr	uccinylcholine. Notify the fistilled water, and admir Supple cacidosis. colding Hanket, cold intra rose, 25–50 g intravenous	e surgeon. Call for nister 2.5 mg/kg <b>portive</b> nvenous solutions).	OAA Diagnosis v	Clinical suspice	on of MH  Music biops and ICI  Clin vetro-constructi	on test)			Cardiova Respirato Ease of ti Emergen Metaboli	ascular stability ory irritation itration nce ism/toxicity 6 Grading of clini	D H D H H cal properties of	1 1 1 1 1 5	000 = least effe	5 5 1	S H & S D D D	s	
		Discontinue volatelp.     Mix destrolene sa intravenously as s     Administer board     Institute cooling to     Treat severe hype insulin, 10-20 un     Administer antiar acidosis.	tile anesthetic and sa schare with sterile di son as possible. conste for metabolic measures (lavage, co relalentia with destr its intervenously (ad rhythmic agents if no	uccinylcholine. Notify the fistilled water, and admir Supple cacidosis. colding Hanket, cold intra rose, 25–50 g intravenous	re supern. Call for rister 2.5 mg/kg portive.  wenous solutions). sly, and regular to of hyperkalemia and	OA.	Clinical suspice	on of MH  Much biopy and NT  Clin vetro—ponetracti	on test)			Cardiova Respirato Ease of ti Emergen Metaboli Figure 29.4 Pungenc Respirato	ascular stability ony irritation itration nce ism/toxicity 6 Grading of clini	D H D H H H H Cal properties of	I I I I I I I I I I I I I I I I I I I	000 = least effe	5 5 1	S S H & S D D D D D D D D D D D D D D D D D D	s	

	10	.[	N	eu	lsc	M	a	SCI	ule	25	ŀ	ok	ck	in	_	29	en	5	(1	nu	Sc	e	R	2/4	X	IN	·).	
														D		U												
	• 1	nto	odu	ıcti	0/																							
		000	duc	ed	by	In	hale	atio	n,	Regi	one	1	or l	JM	BA													
																ana	1ge	sia										
		<b>De</b> f	F:- (	)ru	3.5	act	<b>S</b> 1	Per	ieh	erc	lly	at	NA	<b>(-3</b> )	HAC	io 1	2.	n us	cle	F:b	ers	to	Ы	cK	‡re	nsw	issi	<b>8</b> 7
																caL												
																of c												
	\															20-1					Neu	ron.	2 m	lusc	le.			
																										oline a	celul	
																										ransk		
	A	ch (	ର		5 6		in	Cuk	uni	k	2	(+)	Ach'	0	R	5,8										יש		
	_	,	٦٣		30	1:22	M C	ha.	nn G			- C. T		la	رمر	, V	He		-	<b>.</b> .	مما	en/	len.	ł				
			Τ,	7							P						5											Г
	. (	?	40	2																								Г
			مامد			A-1	L 10		ماء	- 0			100		لله				0.00	la la	را د ا		مما	۸۱	Pr	olong epori:	ed	
													, As					9	166	y ie	non	(IE)	П	E /-	₹ de	pori	zatio	n
																				<b>6</b>								
																stoo	DI CI		<b>1</b>		•				_	MM	lich.	
1													gor					1					100 1'00			lecen	la la	
																onte			Pro	per	Hes.		,		۳ ۲			
																חנ												
																			10	pen	ing.	08 (	Clos	3	oł I	R ch		el
		<b>→</b> (	Clos	ed (	Cha	nne	LB	bel	1-	Phys	ICA	<b>ly</b> 1	lugs	up	the	ci	enf	eL A				-						
		<b>→</b>	ope	n c	ha	nne	L	Bloc	K⊱	en	en	<b>&amp;</b>	obst	ruc	s	1ch	R	Fh	10	pen	Ing	(A	ntib	istic	3,G	ccir	ie,	-
		+		-9	hil	idi	ne	)L	nte	rFe	rs	wit	<b>አ</b>	JOC.	Cad	e 1	eve	54	).									-
																												-
						lariz								100		lepo			1 1			11						-
				Sr		acting		olin	e							actir acuri		Me	abol	ized l	by ch	onne	stera	se				
				0						d int	ubati	ion		In	tern	nedia	ite-a	ctin	g									
																curiu				ıriur	n Ho	ffma	n					
														F	Rocu	ironi	um;	Vec	uror	ium	Live	r						
														Lo	ong-	Acti	ng											

Doxacurium

Pancuronium; Pipecuronium


1   <b>5uc</b>		<b>1</b> 1.		<i>!</i> _   _	- 11		•						esterase acti	n to decrease
	cinyl	choli	ne (	Suxa	meti	wniun	1).					rug	Descrip	
- 00(0	1. 5.	یو لی	-60	e D	المنم	sezuen	co inc	يلم ال			_	hothiophate	Organo	phosphate use for
•	P											eostigmine		sterase inhibitors
→ b Lif	sid So	lubi lit	y as	mell (	is fe	alive	overdo	se gi	ven.			vridostigmine nenelzine	Monoar	mine oxidase inhibitor
dura	tion .	oct:	an .	Chart	< 1a	min						clophospham		plastic agent
•											M	etoclopramide	Antiem	etic/prokinetic agent
_ <b>L</b> T	by To	pie o	т аы	Me	_ me	abolisn						molol	β-Block	
	Huc	other	mia:	· Irate	of h	ydro lysi.	s.					incuronium ral contraception		oolarizing muscle relaxa agents
		L			_									
						regrency					<b>J</b> S			
	Gen	etali	y Var	icble:	. Het	erozyg	ous or	Hol	MOZY	sous				
						ese in			V					
• I				_			•							
→ inte	ractio	n (ch	lineء	strase	in hi	itors :-	Neosti	gmin	e . py	rodos	tiymi	ne).		
	ralane	abore	T LL	ok .	†Ach	-> td	Paolaris	alia						
	9	Pillade												
					+ Hye	lojy sis	of Su	dnyle	hine	(fb	seud	Pholi	nestr	ale).
Dose	_Ad	سلل ا	inte	belion	·1-	1.5 mg	/Kg.	5 mg	/Ka 6	alone	)			
												14.	10.	
						•			_		L I	119	1500	-locoml
	Lachil	d -in	lubat	ion :- i	nfont	s 2mg	/Kg	, old	er :	1mg/	Ks.	(km	ature	Recept
						tropic					0			'
—)JE [	- CV3													
		10	ose	:- <b>?</b> HR	1 & Co1	ntractil	ity, T	cate	chola	mine				
		Jak	بمليان	n. Ri	aduc.	ardia (	Tv. al	ra oi s	<u> </u>					
	0		1 1		. •		1 - 1	<del> </del>			1			
	>FQS(	icula:	tion:	-Signs	rs out	et of po	valysis ,	prev	entea	ارزا	ion-d	lepola	li zin	gents
Dians causing	_ Mu	algia:	LINS	ichror	ized	Contrac	tion .	tck	2 my	oslobi	nemi	4.1	By N	SAIDs.
Standard Industrian (f)	41					- 1/1							91	
yndrome onti disesse I body immebilization	<b>→</b> I N	- norn	iac i	TIME	. IEIG	SE K T	o ome	3/ L	/ 7	ME		7 184	<b>a</b> 70	cordiec
es) energem ery esta with-meridinale artidenia. Duchemoris dynamatris,	mal	isnant	r hy	erthe	rm la	Topic 9	<b>)</b>							
	الما	ocropi		e luce	. 4T/		Se /		41	ممدلد.		2		-Intubeti
							ZL INA				ina '			
									17 1			L-3 IM	III PIE	- 111/00/2//
						Stone			17 1			2-5 M	III PIE	- 1117(4)-871
	_tintr	agestic	c pre	essure	<u>.1</u> 4	ES tone	not	Refli	ux/e	prieł	ion.			
	_tintr	agestic	c pre	essure	<u>.1</u> 4	ES tone	not	Refli	ux/e	prieł	ion.			مه (عاده
	tintr tint	raccu	c pre	essure ressur	.14 e :-e	ES tone	not	Refli	ix/es longe	prieł	ion.			
	tintr tint	raccu	c pre	essure ressur	.14 e :-e	ES tone	not	Refli	ux/e	prieł	ion.			
	tinto tinto	ragestic	c pre	essure	.14 e :-e	X-re-0	not	Refli	ix/es longe	prieł	o leriz			
Drug	tintr tint	140Cu	pola eimary contraction of the c	essure ressur	.14 e :-e	Vagal Blockade Vagolytic	not	Refli L pro	bnye	Intubation dose (mg/kg)	on Onset action a Intubat dose (min)			Maintenance dosing by infusion
Drug	tinto tinto	Tagastic	polarimary Other	essure ressur rizer	s T LI	X-re-0	not	Refli L pro	Drug	Intubation dose (mg/kg)	o leriz	Of Duration of action (min)	Mainten dosing b boluses (mg/kg)	Maintenance dosing by infusion
Atracurium	NO! Structur  Benarylisoqui nolone	140CM	pola pola pola pola pola pola pola pola	resture resture resture rizer buration ++ ++ ++	S Hist. Release	Vagal Blockade Vagolytic	not	Refli	Drug  Succinylcholine  Rocuronium	Intubation dose (mg/kg)	on Onset a action in Intubated dose (min)	Duration of action of action (min)	Mainten dosing b boluses (mg/kg)	Maintenance Maintenance of Maintenan
Atracurium  Cisatracurium	NOI Structur M III Sensylvaqui andre Benrylvaqui	11-Del	polarimary Other	essure ressure rizer puration	S Hist. Release	Vagal Blockade Vagolytic 0	not	Refli	Drug  Succinylcholine Rocuronium Mivacurium	Intubation of the control of the con	on one carion intubat dose (min)  5-1  1.5-2.5  2.5-3.0	of for deciding (min)	Maintendosing b boluses (mg/kg)	Maintenance Maintenance of Maintenance Maintenance of Maintenance
Atracurium	Not Structur Mr. Berarylisoqui nolore	11-Deli Print Annual Print Annu	oola poola crimary creetio	resture resture resture rizer buration ++ ++ ++	S Hist. Release	Vagal Blockade Vagolytic 0	not	Refli	Drug  Succinylcholine  Rocuronium	Intubation dose (mg/kg)	on one control of the	Duration of acti (min)  5-10  35-75  35-75  30-45	Mainten dosing be boluses (mg/kg)  15 mpdic .05	Maintenance Maintenance of Maintenance Maintenance of Maintenance
Atracurium  Cisatracurium  Mivacurium	Structur M months of the structur M months of the structur M months of the structure of the	190cul 1-Deficial profits a second se	oola rimary O xxeretio 0 t x	essure ressur rizer msc Duration ++ ++ ++ ++	S   Hist. Release   + 0   +	Vagal Blockade Vagolytic 0	not	Refli	Drug  Succinylcholine Rocuronium  Mivacurium  Miracurium  Miracurium	Intubation dose (mg/kg)  1-1.5  .6  .2  .5	n Onset 2 of 1 of	Duration of activiting of activiting (min)  5-10  35-75  35-75  40-75	ion dosing b boluses (mg/kg)  .15 mpshitdoshd5-tskd) .05	Maintenance Maintenance of Maintenance Maintenance of Maintenance
Atracurium Cisatracurium Mivacurium Doxacurium	Structur Mr.  Benny lianqui nulerer Benny lianqui nulerer Benny lianqui nulerer Benny lianqui nulerer	11-Del Per	poola rimary of the control of the c	rizer  rizer	S In Hist. Release	Vagal Blockade Vagolytic 0	not	Reflice A pro	Drug  Succinylcholine Rocuronium  Mivacurium  Atracuriu  a ccuronium	Intubation of the state of the	n Onset iz action in Intubated dose (min) .5-1 1.5-2.5 2.5-3.0 2.5-3.0 3-4	Duration of acti (min)  5-10  35-75  35-75  30-45	Mainten dosing be boluses (mg/kg)  15 mpdic .05	Maintenance Maintenance of Maintenan
Atracurium Cisatracurium Mivacurium Doxacurium Pancuronium	Structur M m  Benery hasqui  nolore	11-Del Per	oola rimary O xxeretio 0 t x	## ## ## ### ### ### ### ### ### ### #	S In Hist. Release	Vagal Blockade Vagolytic 0 0	not	Refli	Drug  Succinylcholine Rocuronium  Mivacurium  Atracurium  cecuronium  ancuronium	Intubation of the state of the	n Onset action in Intubat dose (min)  5-1  15-25  25-3.0  25-3.0  3-4  2-3	Duration of activiting of activiting (min)  5-10  35-75  35-75  40-75	Maintenn on Maintenn dosing b boluses (mg/kg)  .15 mpshi .35 .31 .02	Maintenance of Mainte
Atracurium Cisatracurium Mivacurium Doxacurium	Structur M. Secretian M. Secret	Tetabolis Print A X X X X X X X X X X X X X X X X X X	poola rimary of the control of the c	rizer  rizer	S In Hist. Release	Xtra - 0.0  Vagal Blockade Vagolytic 0 0 0 ++	not	Refli	Drug  Succinylcholi ene Rocuronium Mivacurium Statracurium et ecuronium ancuronium percuronium percuronium	Intubation of the state of the	n Onset iz action in Intubated dose (min) .5-1 1.5-2.5 2.5-3.0 2.5-3.0 3-4	Duration of acti (min)  5-10  35-75  30-45  40-75  45-90	mon Maintenn dosing b on dosing b boluses (mg/kg)  .15 .15 .05 .1 .02	Maintenance dowing by infusion (ug/kg/min)  2-15 mg/min  9-12  1-2

. 11																	
• Non-De	polarize	ינג							-		$\vdash$		<b>A</b> .				
Types -	Benzyli	ozuin	oline	<b>s</b> . 6	lelas	e H	istai	min	e (B	ron	chos	pasr	n,Th	IR, h	ypoł	ent	61
	Steroids	V450	olytic	. , A	llesgi	ic H	listo	cy.									
	steroids others:	Like	chk	srofi	umai	rate	S.										
-intubation	not Re	-pid	as su	ceiny	cloli	ne											
	Quick	led b	y 1do	se o	r Pr	ni.	n d	ose	5	min	befa	ME -	<b>→</b> 0¢	ure l	R-of	oste	۲.
							7			oes	net	lega	1 40	ckn	العا	y Acr	d
										'Auca	وار		ام م	ysph		منا	0
Maintance	Luc	richle	ı in d	<b>0</b> (2)	reco	nce								<b>J</b> -F	رد.ن	4	٦
7-(410) 4110	Re							щ	la.	ام م	1300	لماء	C 1	/ <b></b>			
	L <sub>all</sub>									0-5		14 16	1	(IMOV	EME	nr,	<b>E</b> 1
-11.1.											· 00 ·	.1					
Inhalation	Volati	ile 95	ents	190	se i:	2/.	CTE	nch	anc	2 <i>d</i> (	arti	li Jy	).⊢				
	Des >	>Sev	>15	o A	Enf	ura	ne	<b>&gt;</b>	14101	hand	2 >	N20					
	_ pancu																•
→ Autonomic	SE - +	ubocı	k rari	ne/i	neto	cui	rine	2:-0	ld, f	عاود	K ge	insli	۱) ۵	Con	ract	يوانا	J
	L_p	ancur	roniu	m :-	1vq	gal.	<b>&gt;</b> •	łoch	ycer	die.							L
- Excretion	- Hepal	اد	<b>P</b>	Cur	oniur	n/v	eci	L COTI	ium	me	labo	lize	d by	Live	?C.		
			Liv	er f	aliure	2	10	Anc	urol	iuM	8	roc	uron	lum	Blo	xccK	رو
													ium				
							Na	e	fect	011	C	set	racı	riul	n la	ntac	u
	Renal	- Da	YG E	en.	Ver												
Carlore	Temo	ITan		مادی	لمر	00		/1	لمد	1.1		0 0	لدي م	200			
- Fectors -	Asid Da	D IEIN			Jea		l.		MET	(00))	2 171	964	CVG	toft.			
<b>─</b>	Licid - Res	2 :- K	H →	Prok	nyed	46	тюл	•									
	lk/lca:-																
	tMg: pr	olong	_ (Co	mpe	+10	Ca	, in	pre	ecle	mps	ia)	•					
→Age :- neo	ncte have	e Tser	nsıtivi	ty (1	don't	1d	<b>9</b> 50	) <b>, T</b> (	2x+n	acel	ખેવા	Spe	e (	tų).		-	H
																	L
2 Antracu	rium (1	Benz	ylisos	<u>ui o</u>	line												L
Hoffman	elimination	งก :- <mark>m</mark>	etabo	lizea	lind	epde	enł	of F	Rena	18	bilis	ry a	ute	5.			
doses: His																	
Loudan At						T'											Г
-Laudanos		<b>-</b>	- 61	س ۾ ع	المطد			ca: >	LIFA	00	000	RRP	<b>)</b>				
Laudanos			- cN	s ex	citati	on -	<b>-</b>	seiz	ure:	(Cr	oss	BBB	). 	e Cal	حـــــــــــــــــــــــــــــــــــــ		

3 Cisatracrium (steroisomer of atracrium).	
xu potent.	
Hoffman elimination	
Doesn't produce dose-dependent Mistamine, Ilai	dencine towards
PH / Temp sensitivity - secondary to unique metal	aleas
py remp seintionysecondary to unique meral	ools (t
Laprolonged action by hypother	mra /acigosis.
4 Mivacurium	
metabolism:- Pseudocholinesterase	
cause Histomine relase.	
_duration:-Breif (Half of Otra/vec/ro)	
markedly prolonged by prior adminestration of p	ancuronium.
70 (	
5 Doxacuronium (Benzylisoguinoline).	
exceretion:- Renal (as long acting).	
exceretion:- Renal (as long acting).  -onset:- Slow 4-6 min (0.05 mg/Kg for intubation).	
No cardiac or Histamine-Release SE.	
Duration:- 60-90 min.	
Dancuronium (Steroid Base).	7 Pipecuronium
exceretion primary by Renal	Same As B
Some by Bile (cirrhosis - Adare).	no CVS SE
Exceretion primary by Renal Some by Bile (cirrhosis → tdase).  SE HTN & THR: Vajal block + Symphatic .  Arrhythmias: TAV conduction & Catecholam	Renal excretion
Arrhythmias: - TAV conduction & catecholam	ine relose (9 with TCA & held
Allergic - Hypersensitivity to bromide.	
8 Vecuronium	
excretion:- Renal & biliary.	TABLE 11–8 Additional considerations in special populations.
SE No cvs (topoid - bradycardia)	Pediatric Succinylcholine - should not be used routine Nondepolarizing agents - faster onset Vecuronium - long-acting in neonates
Bulldup 3-Hydroxy - + Tclerance - polyneur	Elderly Decreased clearance – prolonged duration, except with clatracurium  Obese Dosage 20% more than lean body weight;
Sullaup 3-Hydroxy -> I cleratice -> polyneuro	Henatic Increased volume of distribution
9 Rocuronium (Rapid-Vecuronium)	elimination due to hepatic metabolism and biliary excretion Cisatracurium – unchanged Pseudocholinesterase decreased; prolonged
	action may be seen with succinylcholine in severe disease  Renal Vecuronium – prolonged
No active metabolite: Long-term infusion	failure Rocuronium - relatively unchanged Cisatracurium - safest alternative Critically Myopathy, polyneuropathy, nicotinic iii acetylcholine receptor up - regulation
- elimination: Hepatic & Renal (+ in pregrange)	
guick anset, short duration (1 in elderly)	

Slight vasolytic tendencies.  In Antacurium (chlorofumarates).  as Lypohilized powder bec 1ts not stable as an agueous solution duration: Ultrashert. (1-2m) metabolism: nonenzymetic degradation by 2 chemical Reactions. Repid inactive gu Dose: 0.2 ng/kg. (EDqs)  Dose: 0.2 ng/kg. (EDqs)  duration: S-10 min Antidote: edrophonium, cysteine.  SE: after x3 (EDqs) — Cvs (Histamine).  Reversal of NMBA: Cholinegic (National Control Con	1mg/Kg:-↓pa	st-op myalsia	For Succi	ylcholine.			
Gantacurium (chlorofumaretes).   as Lypahilized powder bec its not stable as an agreeous solution   duration: Ultrashart. (1-2m)   metabolism: nonenzymetic degradation by 2 chemical Reactions Reput Inactive Graduration: 5-lo min   Dose: 0.2 mg/kg. (EDas)   Dose: 0.2 mg/kg. (EDas)   duration: 5-lo min   Antidote: edrophonium, cysteine.   SE:-afterx3 (EDas) -> cvs (Histamine).   Reversal of NMBA:-   cholinessic							
as Lypohilized powder bec 1ts not stable as an agreeous solution  duration: Ultrashert. (1-2m)  metabolism: nonenzymetric degradation by 2 chemical. Reactions Rapid inactive cys  Dose: 0.2 mg/kg. (EDas)  duration: 5-to min  Antidote: edrophonium, cysteine.  SE: after x3 (EDas) — CVS (Histamine).  Reversal of NMBA:  cholinestic Degradation by atropine (anticholinegic)  cholinesterase inhibitars (neostigmine)  Also tach in muscarnic CVS: Bradycardia  also tach in muscarnic CVS: Bradycardia  the only time after succinylcholine is when there is phose II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relevant-binding agent tight camplex 1:1 with steraidal NMBA.  The never neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents, they undergo chemical degradation by rapid adduction with L.							
as Lypohilized powder bec 1ts not stable as an agreeous solution  duration: Ultrashert. (1-2m)  metabolism: nonenzymetric degradation by 2 chemical. Reactions Rapid inactive cys  Dose: 0.2 mg/kg. (EDas)  duration: 5-to min  Antidote: edrophonium, cysteine.  SE: after x3 (EDas) — CVS (Histamine).  Reversal of NMBA:  cholinestic Degradation by atropine (anticholinegic)  cholinesterase inhibitars (neostigmine)  Also tach in muscarnic CVS: Bradycardia  also tach in muscarnic CVS: Bradycardia  the only time after succinylcholine is when there is phose II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relevant-binding agent tight camplex 1:1 with steraidal NMBA.  The never neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents, they undergo chemical degradation by rapid adduction with L.	1. Gantacuriu	m (chlorofun	narctes).				
duration: Ultrashort. (1-2m)  metabolism: nonenzymetic degradation by 2 chemical Reactions. Rapid inactive cys  Dose: 0.2 mg/kg. (EDas)  duration: 5-lo min  Antidote: edrophonium, cysteine.  SE: after x3 (EDas) -> CVS (Histamine).  Reversal of NMBA:  cholinestic (Philos: Ach, O by muscle relevant  muscarinic: Ach, O by atropine (anticholinesic)  cholinesterase inhibitors (neostigmine)  thach -> Reestablishing normal NM-Transmition.  also 1 Ach in muscarnic CVS: Bradycardia  city: Diarrhes, vomiting, nausea.  the only time after succinylcholine is when there is phase II block & sufficient time has passed.  Sugammadex (cyclodextrin)  selective relaxant-binding agent -> tight camplex 1:1 with steroidal NMBA.  2 mg/kg., 2 - 4 min (1 dose -> 1 effect)  no CV3, RS, Coajulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents they undergo chemical degradation by rapid adduction with L-				table as an a	weaus sale	tion	
metabolism:- nonenzymetic degradation by 2 chemical Reactions, Rapid Inactive Cys.  Dose:- 02 ng/kg. (EDqs)  duration:- 5-lo min  Antidote:- edrophonium, cysteine.  SE:- after x3 (EDqs) -> cvs (Histamine).  Reversal of NMBA:-  cholinessic@ Nicotinic:- Ach, © by muscle relaxant  muscarinic:- Ach, © by atropine (anticholinesic)  cholinesterase inhibitors (neostigmine)  thach -> Reestablishing normal NM-Transmition.  also 1 Ach in muscarnic  CVS:- Bradycardia  GIt:- Diarrhes, vomiting, nausea.  the only time after succinylcholine is when there is phase I block & sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relaxant-binding agent -> tyst amplex 1:1 with steroidal NMBA.  2 ng/kg., 2 - k min (1 dose -> 1 effect)  no cvs, RS, coasulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents they undergo chemical degradation by rapid adduction with L-	duration, ult	cashact (1-9					
Dose: a 2 mg/kg. (EDqs)  duration: - 5-lo min  Antidote: edrophonium, cysteine.  SE:-afterx3(EDqs) -> cvs (Histamine).  Reversal of NMBA:-  cholinessic - Ach, O by muscle relevant  muscarinic: Ach, O by atropine (anticholinessic)  - cholinesterase inhibitars (neostigmine)  - thch -> Reestablishing. normal NM-Transmition.  - also t Ach in muscarnic  - cvs: Bradycardia  - cvs: Bradycardia  - the only time after succinylcholine is when there is phese I block & sufficient time has passed.  - Substicient time has passed.  - Sugammadex (cyclodextrin)  - selective relevant-binding agent - tight amplex 1:1 with steroidal NMBA.  - 2 mg/kg, 2 - k min (tdose - teffect)  - no cvs, RS, cogulation SE.  - not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L				hi g hansa	/ Pacellane	Post inc	مرايم مرد
Antidote: edrophonium, cysteine.  SE:-afterx3(EDas) -> cvs (Histamine).  Reversal of NMBA:-  cholinessic - Ach, Oby muscle relevant  muscarinic: Ach, Oby atropine (anticholinessic)  cholinesterase inhibitars (neostigmine)  Antidote: Ach, Oby muscle relevant  muscarinic: Ach, Oby atropine (anticholinessic)  Antidote: Ach, Oby muscle relevant  muscarinic: Ach, Oby muscle re	Melabolisin:= Ita	IVA (CNA)	ae ji aa ailoi	Zenemica	, NEGLIJOIS	Actor VI	Live cys
Antidote: edrophonium, cysteine.  SE:-after x3 (ED45) -> CVS (Histamine).  Reversal of NMBA:-  cholinesic	Jose - 62 mg	Thy. (EDAS)				Sester ny	alolariz
Reversal of NMBA:  cholinesic Dentric: Ach, Dy atropine (anticholinesic)  cholinesterase inhibitors (neostigmine)  Thach - Reestablishing normal NM-Transmition.  also that in muscarnic Cus: Bradycardia  the only time after succinylcholine is when there is phase I block & sufficient time has passed.  Sugammadex (cyclodextrin)  selective relaxant-binding agent - tight complex 1:1 with steroidal NMBA.  2 mg/Kg, 2-4 min (tabe - teffect)  no cvs, RS, coagulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-							
Reversal of NMBA:  cholinessic & Nicotinic: Ach, & by muscle relevant  muscarinic: Ach, & by atropine (anticholinesic)  the muscarinic and NM-Transmition.  also the in muscarnic & CVS: Bradycardia  call a Diarrhes, vomiting, nausea.  the only time after Succinylcholine is when there is phase II black & Sufficient time has passed.  Sugammadex (cyclodextrin)  selective relevant-binding agent at the time has passed.  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-							
cholinesterase inhibitors (neostigmine)  then Reestablishing normal NM-Transmition.  also 1 Ach in muscarnic CVS:- Bradycardia  the only time after succinylcholine is when there is phese II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relaxant-binding agent typh amplex 1:1 with steroidal NMBA.  2 mg/Kg, 2-k min (t dose teffect)  no cvs, RS, coajulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	,SE:-afterx3(	ED95) → Cv	s (Histan	ine).			
cholinesterase inhibitors (neostigmine)  then Reestablishing normal NM-Transmition.  also 1 Ach in muscarnic CVS:- Bradycardia  the only time after succinylcholine is when there is phese II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relaxant-binding agent typh amplex 1:1 with steroidal NMBA.  2 mg/Kg, 2-k min (t dose teffect)  no cvs, RS, coajulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-		0 0 0 0 0					
cholinesterase inhibitors (neostigmine)  The hard of the second of the	<ul><li>Reversal</li></ul>	of NMBA	:-				
cholinesterase inhibitors (neostigmine)  The harmonic suffered in muscarnic color of the color	_ cholinessic®	Nicotinic :- I	Ach, Oby	muscle relex	ant		
cholinesterase inhibitors (neostismine)  Also TACh in muscarnic  CVS:-Bradycardia  C		_muscarinic:	-Ach, Oby	atropine (a	Hicholines	د) (ا	
Then Proposed the state of the	cholinesters	e inhibitors (	eostiami	ne)		Muscarinic si	Organ System Nuscarini Effects Cardiovascular Decreases
also then in muscarnic CVs:-Bradycardia  Git: Diarrhes, vomiting, nausea.  Latrapine Sulfete or glycopyrolete  The only time after Succinylcholine is when there is phase II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relaxant-binding agent - tight complex 1:1 with steroidal NMBA.  Lang/Kg, 2-4 min (tase - teffect)  No CVs, RS, Coasulation SE.  Not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	AAch - R	es tablishine	normal	NM Transmit		effects of Cholinesteras inhibitors:	Pulmonery Bronchosy bronchisal secretions
the only time after Succinylcholine is when there is phese II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relevant-binding agent - tight complex 1:1 with steroidel NMBA.  2 mg/Kg, 2 - k min (tdose - teffect)  no cvs, RS, coasulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	010 104	in participation	C 1/C	Roady condic		Prizing epathetic according	Cerebral Diffuse excitation  Gastrointestinal Intestinal increased
the only time after succinylcholine is when there is phase II block & Sufficient time has passed.  Sugammadex (cyclodextrin)  Selective relaxant-binding agent - tight complex 1:1 with steroidal NMBA.  2 mg/Kg, 2-k min (tdose - teffect)  no cvs, RS, coasulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	HOIS THUI	III MUSCAIMIC	011	Dischas same	11.00 0000	2 1 / 2	Genitourinary Increased bladder to Ophthalmological Pupillary
Sugammadex (cyclodextrin)  Selective relevant-binding agent - tight complex 1:1 with Steroidal NMBA.  2 mg/Kg, 2-4 min (tdose - teffect)  No cvs, RS, coagulation SE.  Not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-				Distince , vom	iting , liqui	za.	constrictio
Sugammadex (cyclodextrin)  Selective relevant-binding agent - tight complex 1:1 with Steroidal NMBA.  2 mg/Kg, 2-k min (tdose - teffect)  no cvs, RS, coagulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	11 +411api/	e suirete or	Sigcopyron	re		1	1 . I. D
Sugammadex (cyclodextrin)  Selective relaxant-binding agent — tight complex 1:1 with Steroidal NMBA.  2 mg/Kg, 2 - k min (tdose — teffect)  no cvs, RS, coegulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar-izing agents; they undergo chemical degradation by rapid adduction with L-	The only to	ime after s	uccinylcho	gue is Myeu	there is	bucie II e	lock &
Selective relaxant-binding agent → tight camplex 1:1 with Steroids L NMBA.  2 mg/kg, 2 - k min (tdose → teffect)  no cvs (RS, coagulation SE.  not effective on Benzylisoguinoline  The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	Sufficie	nt time has	beried.				
The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	Sugammade>	< (cyclodextri	n)				
The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	selective n	elexant-binding	asent -	ight complex 1	.:1 with !	steroidal N	UMBA.
The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	$\rightarrow 2 mg/Kg$	, 2 - k min (	tdose -t	effect)			
The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	no cvs, R	S, Coasulation	SE.				
The newer neuromuscular blocking agents, such as gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-	_not effect	ive on Ben	zylisoguin	oline			
gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-							
gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-							
gantacurium, which are still under investigation, show promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-							
promise as ultrashort-acting nondepolar- izing agents; they undergo chemical degradation by rapid adduction with L-							
undergo chemical degradation by rapid adduction with L-							
cysteine.		undergo chemical	l degradation b	y rapid adduction	with L-		
		cysteine.					

11.	2/4	XAQI	ia	2	0	th	eſ	DL												
	6			~				6												
· Noma	illy (	02																		
from a	atmos	phere t	to al	veol	ان جے نا	air	21%	,0	pre:	sur	2-	Alu	eo l	_	CA	pill	agy			
					Leppe	artial	press	ure.	<b>—</b>	Atı	nos	phe	ric	Qir	= 14	6 m	m H	(2	l Kp	١).
→ Ar	erial	/venou	5 03	Co	ntent	<b>\\$</b>			H	Hu	mid	ifie	d t	facl	rea	90	s:-  \	Som	nlly	(19
	.34 x <u>1</u>	H x Svo	<u>,</u> )+ (0	.00.	x Po	•).			H	Alv	<b>/</b> eol	ar 1	gas	- lo	6 m	MH	<u>_</u> (l	uKp	a).	_
0	1 0	Class -			96.	19	1 /-	1.0										(13.		
	OF U	2 Flux 1 500-7	la vine	7	- 030-	-   <i>200</i> N	16/1	71111	7	С <b>а</b> ј И:	1	J	وها و مندراً	4	u3-	אר ככ אבו		) (s	)	Pe. Va
	CORSU	mption		) X	A con	leaf n	ni x ec	V.	Can	en.	1	91	) 	2 da	mal	/ma	in	) De	4)	NP.
		ever,s														Oxvhem	oglobin o	dissociatio	on curve	
	1:- ce	oolins,	Para	<b>48 i</b> 5	Med	hanic	el v	rent	ikł	ion						N N		Martin Sugar Landy		
		9.	'													S Standar of females	/-	District Let 100 at 100	W Ni	
<ul> <li>Hypox</li> </ul>	ia :-	Oz for	· tissu	ue 1	espira	tion										***	Poly Poly Poly Poly Poly Poly Poly Poly	se d Ooger POJ		
Anexid	a = ab	of O	in .	lissu	e (c	ardiac	arre	s <b>ł)</b> .									· 0	xygen co	ntent	_
Hypox	emia :	. Jo <sub>2</sub> 1	LuL i	n 4	rterial	bloo	<b>d</b>									Origina somesti de Bassagleksa rossor Prizz Ch Sal	rate (SAC) produce (SAC) produce (SAC)		L	
Acute		uses_	_,Re	spire	story o	lepres	XioN									-	Perjust.		1 21	_
( <del>&lt;</del> 3ω)			- Air	wey	obstr	uction	1													_
			→ Ato																	
						perfus														-
			•	unc	Honal	resid	ual (	ppcc	<b>b</b> .						l.					
	→ Di	med ef	rects.	-	CAUO				nee			02								
		Csigns		<b>~</b>	Excit	(SOT)	DLOC	21116	<b>E33</b>		H	46	7.: 7	- M	eta	- 10	1)29	i <i>(Me</i> iM	:गा . क्टेंट	
				-	Head	ache					•							ess.	1 .	πε
				•	Nous						<b>-</b>	DJ.				JUO	VI)[]	E33.		
					Hunc	ard Isl	De	rea	ian											
					Arthy	mia														
					Bred	ycardi	a													
					Rend	ycardi Lim	parir	nen	ł_											
	L_in	direct	effec	_	. Słimu	detion	of	baro	rec	epto	rs									
		(Signs)		L	Tach	gcardia														
					HTN															
					Hype	rvent	: lati	60												



1 Voriable performance face mask \_\_ flow: 5-101, fig: 40-60%, allow entery of room air, Islaw system - plastic body + 2 side holes + port (+02) + elastic band (+Face) + fig dependent on of flow rate, size of of reservior & Respiratory pattern. indications: when fixed oxygen concentration is not critical. \_contraindications: pt who depends on hypoxic drive (COPD). Adv:- Comfort, simple, I cost, manipulate fioz without changing appliance, + bronchodilator pollado: no expiratory phase, Rebreating (dead space), Tight Atting - 1 Rebreathing, no oral feeds Face Mask with reservoir bes (600-800 mL) partial rebreather - flow - 6-lol/min, Fioz - up to 70% - Adv: plastic bass are transparent under chin (comfortable) diedu- Same as face mask, OBronchodilator therephy, Bad seal - Bad o, deliver Non-Rebreather: flow: 10-15 L/min , fioz :- up to loo/. expiratory parts covered with flaps -one way valve - expired air out no nom ar inhalation Disedv:- Risk of suffication if the gas flow is interrupted. indications: hypoxemia (+face mask) with normal respiratory pattern. face mark can cause drynes of eye (Leaking) , not sativable for pt. Who are claustrophobic Nasal cannula: - flow: 1-6 L/min, Fioz : 24-40% 2 prongs which protrude 1 cm in nose held by head strap. Adv:-Long term usge, 1 compliance, pt. can est, drink & talk. disedu:-trauma & irritation of neal mucosa. contraindication : pt. who requires thow of 02 (tventilatory demands). Expired gas Expired gas one-way valve Inspired gas one-way valve \_ 100% Oxyger High FiO<sub>2</sub> delivered Low FiO<sub>2</sub> delivered Low peak inspiratory flow rate High peak inspiratory flow rate Slow respiratory rate High fresh oxygen flow rate Tightly fitting face mask Fast respiratory rate Low fresh oxygen flow rate Less tightly fitting face mask Mixed Reservoir bag Reservoir bag Non rebreather Partial rebreather mask system

	Venturi principle Admospheric http://pressum Funnelshaped	et .		
2 Fixed performance	Gas Decreased pressure zone	Vaccoum Intellig	Cutter Sunday artists Mark of presents Less FELA	
	Gas injector Exhaust	Various is formed here when as is formed here when as is formed at high selection.		
venturi mask :- Hish-airflow o	oxygen enrichment.	Venturi v	alve	<u> </u>
l plackers below transfer				
plastic+2 holes + venture indications:- dependent	anvere (colored —	Blue 24%		
indications:- dependent	on hypoxic drive (cop	White 28% Orange 31%		
Adv:- No rebreathing & r	not in dead space	Yellow 35%	8 L/min	
		Red 40% Green 60%		
Lydisadv:- Bulky & noisy.				
مرور میرادی میرادی میرا	v. co machanical v	ml·ladiaa		1
non-invasive positive pres	sure mechanical ve	STATE INTO TE		
used to treat acute o	r chronic Kespirator	y feligre, no ri	sks of tracheal	Lintube
Requirement conscio	us of			
/ _   _   _   _   _   _   _				
Coopera	ative.			
protecte	ed airway reflexes.			
		. Нас. С пос		
	vitals & Respiratory	patieth & HBW	<b>}</b> •	
BIPAP (Bilevel positive	girway pressure).			
Mask with silicon co				
pressure 1: inspir	ratory positive airway	pressure.		
	atory positive aimay			
1mean airway pressun	E(then CPAP)→Recruit	ment of alveoli —	Thung complie	nce → i
Disady: abrade the 1	nose. claustrophopia			
indications - signs o			: OF accessory	nuxe)
Las exc	hange abnormalities	(PH< 45)		
	rusmmy, Paoz: Fic			
			0 1	
L. Acute	exacerbation of COPD	with hypoxemia	a & cardiogenic	: edem
	Absolute: RS 8 cvs a	rrest.		
	عدمه المام	46 4 4		
	Relative discomfe			
	TRisk of	aspiration (impair	ed mental sta	tus)
	Active v			
	Large Vo	dume of secre	tions	
	Recent	upper airway o	c CIt Surgery	
CDDD (a alsoure a a				•
CPAP (continuous pos	itive airway pres	sure).		-
Spontaneously breati	ing at a positive end	expiratory pre	ssure, TFRC	
indications: OSA +	D:000 : d: d:			
Indications: OSFI +	BITHP INGICATIONS			
Disadv:-does not as	ugment the tV which	h Limit it use	in Acute RS	faliuse

											OW vern NO		
PEEP (pe	sitive en	d expi	rataru	Dress	ure).						The control of the co		
→ an col			-	1,000							Mechanical ventiliation and CRANED  offers bearing the result in the committee of the commi		
											independent of the control of the co		
int ub	ated by	511. . 11		1. 1	1/2 -				<b>U</b>			1.	
	ere Kept						pen	QT '	me e	na (	H expi	Mi	on.
<b>→ № ③</b>	pressure	is appli	ed to	inspi	Catio	n.				Fixe Non invasive	l Performance mechanical ventilation		
0 . 1/	14 1		1/	1 .						American American	<u> </u>		
Bag-Ma													
Bas+0	, one-	way val	ne t3b	orts Cir	ılet, ı	outle	, M	nK ( fe	de),	reser	vor for	02.	
	es good						-						
Diffuc	ult:- fasci	al Hair	, obese	, Aze	>55	, Lack	l of	teeth	, Histo	gy of	Snoring	<u>.                                    </u>	
Types	tvalue	:- More	than 9	d. 02	to v	entik	ted	I spo	ntan	ous b	reathing	pts	
	valve	e:- tcon	c. 02 d	uring	PPV	but o	nly	36/.	ducing	Spo	ntanou	s bre	eaths.
indice	tions:- RF												
	indicatio												
	simple,								De				
	:-opens					nctica	. un	contr	Jled	hung	rvent	leke	
	- OPEN		P11 41 10	,,,,,	-u pi	461166	, 411			ייוכיי	7 7 6 11 11	14110	
pediatr	cs (was	ر جالم:	o edera	Manca	day	رم:							
incubato		nadae 9	in Con	L	aev	ice).							
ILIC U PAIO	_ Flow	relo.	o Kl	is only	Cal	10. (	5.7						
	PION	· Iaie:-	8-12 L	Min	102:	- 40-:	00/.	11	. 1.0.		0	1.1.	
	Provi	iae ne	utrac '	merm	al ei	nvicon	men	T, hun	Ni <b>cl</b> it i	<b>c47</b> iOl	1 4 02	aeli	very.
	Latron				<b>eliza</b>	tion	OF T	he pt					
→Hood _	neongre	s & infa	ents of	nly.		0	.,		-	259	1	Oxyg	en hood
	flow ra								Pos	liatric incuba	tor	DATIT	
	provide	control	of te	Mp , h	umid	lty &	02.		-	natric incube	tol	4	tent
	Transpar	rent :- a	llou V	isueliz	ation	of 1	the	<b>st.</b>					
tent	pt. can	move	aroun	d in h	is be	d wi	ithou	t fac	e Me	K.			
	used fa	or Kids											
	maintain	humic	lity.										
	maintain flow rate	2 :- 12 - I	5 L/mi	n Fio	<u>:- U</u>	o-50	<b>7</b>						
	Guideline for o hypo	oxygen thera oxemic patio		ely	[	Aim for Sp0	02 94-98%		-	II:			
	Assess Airway, Breathi When the patient is at Target saturation is 88	t risk of Respiratory	type II failure:			<ul> <li>Comment face mask</li> </ul>	ce oxygen at k 5-10L/min.	air or oxyger 2-6 L/min via n Reservoir Bag 1	asal cannula or	simple <85%			
	ABGs result :  When pH<7.35 and PG senior review and con	CO2>45mmHg (6.0 kP	a) seek immediate	ith		1. PCO SpO	2 94-98%.	6.0kPa) treat appro					
						2. PCO	E = 45mmile (4	o.okraj or respirat					1
	the lowest FiO2 to kee NIV/MV  When pH>7.35 and PO lowest dose venturi m ABGs at 30-60 minute	ep SpO2 88-92% eithe CO2>45mmHg (6.0kP;	er via venturi system	n or	-	imm urge chro	nediate senior r ently aiming for onic type II resp	review and consider r SpO2 94-98% con piratory failure. If li -60 minutes for all	r invasive ventilat sider COPD or und kelv aim SpO2 88-	on . Treat liagnosed ——— 92%			


10 0 11				- 0				
12 - Anesth	esia mo	nitoring	in (	DR &	L 1CL	)		
• introduction								
past Visual	monitoring	of Respire	ation 2 c	verall	clinical a	pperance		
L- Finger	on pulse 2	BP.						
→why? — mainta	in normal pl	ysiology &	hemeos	asis th	roughout a	nerthesis	& Sugges	
- Sugery	is very str	essful : Syn	phatic :	stimmul	ation , HT	v, techyc	ardia arrh	ythm
SE of at	esthetics:-h	emodynami	instab	ility , m	yocardial	depressi	ion Hypoles	Hion
Blood	loss , hypo or	hyperveni	ilation .	Hypoth	ermia.	•	<b>J</b>	
2 critical time	es:- induction	n & Reco	very.					
consist of	sensory for	data coll	ection	Eca L	end out	e oxime	etre).	
	system dat	analysis						
	ystem for i	nterpretat	ion & di	splay (or	Screen)			
Degree of invasion	veness	Non-invas	ve :- att	ached	to skin	(ECG)		
999		penetratio	9:- Norr	na/ pas	ese thre	ush the b	ody (ECH	o)
		invasive:-	Abnorma	L Desse	se (Arte	iel Line	(CVD)	
		Highly invas	ive:- in	side or	en (PAC	Brein)		
Limitation (5D)	. Delay	09					•	
	Danjer.							
	Dacrease	ckill .						
	Doubt of							
	Distracting							
ASA Guidelines			الموم أح	hecia a	eccanoel	chall be	accord	
	Standard II							المعاد
		ventile	tion (co	DNOSTOC	L. (TV)		PRISE OXIIN	
		Circul	Jan (2)	and Ec	RP (a	S min )	continu	ally
		Ctemp (	Lema a	rota)	, 51 (7	9 10 101 7	evalu	ated
select a monitor	Aim	- rempt	temb b	1005)			1	
Depends on:-			Cvs		Rs		Invasive	
Depenas on:	Experience True of or	e di e	Periphera     Tissue pe     ECG.		Clinical more     Airway pres	nitors. sure measurement. on alarm.	_	
	Type of an	nesmesia a.a.l.l.l.l.l.	Arterial b     Central ve     Pulmonan		Disconnecti     Stethoscop     Spirometer     O2 monitor	on alarm.	Arterial line     Central venous pressu     Pulmonary artery cathet     ICP monitoring	ire terization
	Malures Q	GVGIICOILITY			• Co2 monito • Anesthetic • H+ ions me	ring. gas analysis. asurement.	ICP monitoring	
	Nature of	surjery.			Ns		Cns	
	pł. Genera	c condition			Peripheral nen	e stimulation:	Clinical monitoring.	
			Temperat Tissue ox Indirect o Fluid & e			witch. four twitches. stimulation. burst stimulation.	Clinical monitoring. EEG.  Evoked potentials. Cranial nerve monit Cerebral blood flow cerebral oxygenation	toring.
			Blood ga monitoring		s 4) Double	burst stimulation.	Cerebral blood flow     cerebral oxygenation	on.

 R5 monitors oxygenation: Ensure adequate of conc. in inspired gas & Blood & delivered to tissue. methods - Exposure to assess color \_\_ inspired gas oxygen analyzer # \_\_\_\_\_\_#70 \_\_puke oximetry. 36 \*\* VVV Property Pr -monitor o, delivery to pt. 02 fallure alarm (ges supply pressure monitor). oz conc. in the gas mixture (Fioz analyzer). monitor of delivery to tissues clinically:- cap. Refilling, state of extremities Oz transport: Hb Lul, SaOz & PeOz De uptake (utilizing):-SVOz (PAO), Lactic acid Lul. pulse oximetry Deff: / of oxy-Hb/Total Hb. Timing: Before induction - after recovery. poplical plethysmography: detect pulsatile (changes in Blood volume, pulse wave). spectrophotometry: measure pulsatile (Hb saturation). Value - Spo2 peripheral perfection state (I waveform - Hypoperfucion: hypotention cold) idea about thythm from plethysmography wave (irregularly not type). cardiac arrest (Abs of wave) How? - Finger or toe (without neil polish astems). to the Limb with Iv Line (opposite the Limb with BP cuff). → Readings -- normal person on roomair (0, = 21%):- >96% pt. under GA (100%.02):-98-100% (not accepted under 96%). - Hypoxemia: <90% (Peo2=60mmHz) Sever Hypoxemia: <85% inaccuracies misplaced on the pts finger, slipped. pt movement shivering. poor tissue perfusion (cold extrimities. Hypotensian, shock). cardiac arrest interference \_\_intrinsic:- co-Hb, Met-Hb, IV dyes, Fetel-Hb L. Extrinsic: motion, caulary, nail bed infection, polish


	ion							
meth	ods qua	litative signs	chest	excussio	n			
			obser	vation o	f reservo	ir bas		
					of breath			
	que	nklive measu					he).	
				Volume	of expired	Acc.		
				Airway f	•	י <i>ד</i> ט י	expiratio	n
CARACT	ahu. Co	hiovef- acc			7.53415			UC). 2-lightr 1064
		Waveform			(110) - 1 -		inspiration ir	nspirat
E1CO <sub>2</sub>	- point in	capnogram,	enapoint e	expiratory (	Highest Co	2/:		
		o-35mmHg (		en Pecoz	by 5-6ma	My). Re	spiratory system monitors Capnography	3
Ly Value		ophajeal intu				P	hases of the capnogram	on a Normal Co
	ventilat	ion: hypo or	hyper , c	urare clel	<b>P</b>		Upstroke: B-C Plateau: C-D End-tidal: point D	l.
	pulmona	ry perfusion	:- pulmon	ery embo	lism		Downstroke	All home follows
	Breathi	ng circut :- a	isconnect	on , Kink,	obstruction	, rebreat	ling	
	cardiac	arrest:- prog	nostic val	ue, adeni	vecy of re	sucitatio	n during a	m
	metab	oke State						
CVS m	miles							
		ous electro		4 4 - 4				
ILC INOUS			-draiogra	THE WISHITS	177			
	-Arteria	l BP						
	<b>→ NK</b>		•					
ECG -> V	lue HR	R wave co	enting					
	Rhy	thm :- I→s	upraventr	icular arr	hythmia,	All Leads	→ventricu	la
	isc	hemic chang	es & 57	Serment	analysis.	(IL.Ve.V	(L)	
Tin	ning:- throw	shout the s	urgery! Bo	efore ind	uction un	til after	extubetion	2
	es3 L	eads :- Red:	Rt yell	ou:Et	Black :- Ad	ex.		
To	SI.	eads :- Red & y	ellow som	e Bleck	under red	Greenun	der vellen whil	. م
<b>+</b> Ty	00	Chapt much	مملا ها	الملم الم	LIMPS AL	silent -	nonince	
<b>+</b> Ty	lesQR	s beep must			times. No		nonitors.	
<b>+</b> Ty	les — QR	s beep must utery artefo			times. No		nonitors.	
→ Ty → Ru	es QR.	S beep must utery artefo hythmias —	ets ECa	-check	times. No cradial p	ulse.		1
→ Ty → Ru	es QR Cal Arr sive BP	S beep must utery artefo hythmias — methodo	els ECG	cillomet	times. No cradial p ric algoria	hms. /A	utomsted	
→ Ty → Ru	es QR Cal Arr sive BP	S beep must utery artefo hythmias —	els ECG	cillomet	times. No cradial p ric algority Small-	hms. /A - false	ułomsted 18P	•
+Ty	es QR Cal Arr sive BP	S beep must utery artefo hythmias — methodo	els ECG	cillomet	times. No cradial p ric algoria	hms. /A - false	ułomsted 18P	•

value	avoid & manze Hypo or HTM.
	Avoid JMAP< 60 mmHz (cerebral & renal prefusion).
	Avoid Idiestolic BP.
	Risk of HTN, cvs:- MI, PE
	CNS:-hemorrhyic stroke, HTW encepholopathy.
	Disk of Lu Louis - nemotingite strong, it we encephatoparay.
	Risk of hypotension Cvs:- MI
	CNS:- ischemic shoke, Hypoperfusion (MA)
Timing:	:-throughout the surgery: Before induction until after extubation & rewn
frequen	every 5 min :- after spine Anesthesia, Hemodynamic instability.
	every 3 min : after spinal Anesthesia, Hemodynamic instability.
	every to min :- awake + Local (monitored anesthesia care).
monitoring	a of metabolism
• TEIMP - Si	ites Tympanic
	Esophajus  Bladder
	Bladder
<b>     </b>	
	Blood (PA cath, most sensitive)
	Skin.
	normal loss: 0.5-1°c/hr, not more than 2-3°c.
	complications of hypothermia cardiac anthymias:-VT & arrest.
	myocardial depression
	-Delay recovery (delay drug metaboli
	metabolic acidosis (Lectic acidosis)
	- HyperKslemia
	Coesulopathy.
Nusamusa	cular function (Evaluation of Block)
	nerve stimulation Single twitch.
Perpreta	
	Train of four twitches
	Tentanic Stimulation.
	Double brust stimulation.
-clinically Bl	Nockede Reversal — Head lift > 5 seconds Sustained hand grip
clinically Bl	Lacks de Doug (Ca) Head lift > 5 seconds

• invasive mo	nitoring.
Aderial Line:	- best-to-best monitoring of ABP.
indications.	Rapid moment to moment BP change (pheochrocytoma surgery)
Indications —	frequent Blood sampling (ABGs)
	circulatory therapies (Bypens, IABP, vasoactive drugs).
	Faliure to inderict RP (Burns, morbid obesity).
- Radial Art	ery cannulation Technically easy
	good colleteral (ulnar)
	Complication uncommon.
Brechiel	Longer catheter to traverse elbow Joint.
	postop Keep arm extended
	no good colletered.
	Philis Pressure Sup - Old Olumbing persone Olumbing persone
remotal +	use guide-wire technique.
	puncture femoral artery below injuinal Ligament (easser to compress)
<b>L</b> complication	ns Early Hematoma
	Vasospesm
	Nerve dame
	Late Thrombosis
	Embolization (air or thrombus).
	Skin necrosss, infection
	SAMI NECTONS, INFECTION
	Disconnection & Fetal Blood Loss.
central venous	
indications	CVP monitoring
	Advanced CV disease + major-op.
	Secure Vascular acess for drugs (vascactive)
	acess for flinds
	inadequate peripheral IV acess (obese).
	Pacer, Swan Canz (pulmonery cath).
ا عمام: ١٩	Jugular Consident, predictable anatomic Location.
TATE INTERNET	On the stable distance with the stable design of th
	Readily identifiable Landmarks.
	short straight course of SVC
	Easy intra-op acess for anesthesiologist at pt's Head.
	tsucess rate (90-99%).
	Disady:- discomfort



Respiratory falture introduction inability of Hypoxem Hypoxemia: 402 in Arte Tissue hypoxia: 402 delive Hypercapnea: arterial Co depends on CNS (media  NM-Junca (disphress & RS m	of Lung- lia or crial blood vered to 2 particular alla a phro	ho meethypercond systematic Nice Nice Nice Nice Nice Nice Nice Ni	t the capned em ( ) issues were >	metal a. Pa02 < Drug on Stroke Traumors Tumors	bolic d	<b>н</b> у)	ids)	PH acido  PH 7.85 - PH 7.8	AL BLOOM RPRETATI
Respiratory Falture  introduction	of Lung- lia or crial blood vered to 2 particular alla a phro	ho meethypercond systematic Nice Nice Nice Nice Nice Nice Nice Ni	t the capned em ( ) issues were >	metal a. Pa02 < Drug on Stroke Traumors Tumors	bolic d	<b>н</b> у)	ids)	PH acido  PH 7.85 - PH 7.8	ste < 7.4 > 4.5 pu - (n - 10 g) ste
introduction inability of Hypoxem Hypoxemia: 102 in Arte Tissue hypoxia: 102 deliv Hypercapnea: arterial Co depends on CNS (media  NM-Junce (disphress & RS m	rial blood vered to 2 partial alla a phro tion muscles)	Hypercold Systematics N)  I pressuenic N)  myer  police  Guill	em () sissues ure >	a. Pa02 < Drug of strake Traumors Tumors	somming.	<b>н</b> у)	ids)	PH acido  PH 7.85 - PH 7.8	ste < 7.4 > 4.5 pu - (n - 10 g) ste
introduction inability of Hypoxem Hypoxemia: 102 in Arte Tissue hypoxia: 102 deliv Hypercapnea: arterial Co depends on CNS (media  NM-Junce (disphress & RS m	rial blood vered to 2 partial alla a phro tion muscles)	Hypercold Systematics N)  I pressuenic N)  myer  police  Guill	em () sissues ure >	a. Pa02 < Drug of strake Traumors Tumors	somming.	<b>н</b> у)	ids)	PH acido  PH 7.85 - PH 7.8	ste < 7.4 > 4.5 pu - (n - 10 g) ste
Hypoxemia: 402 in Arte Tissue hypoxia: 402 deliv Hypercapnea: arterial Co depends on CNS (media  NM-Junc- (diaphress & RS m	rial blood vered to 2 partial alla a phro tion muscles)	Hypercold Systematics N)  I pressuenic N)  myer  police  Guill	em () sissues ure >	a. Pa02 < Drug of strake Traumors Tumors	somming.	<b>н</b> у)	ids)	PH acido  PH 7.85 - PH 7.8	ste < 7.4 > 4.5 pu - (n - 10 g) ste
Hypoxemia:- 102 in Arte Tissue hypoxia:- 102 deliv Hypercapnea:- arterial Co depends on CNS (medu  NM-Junce (disphress 2 RS m	rial blood vered to 2 particular alla a phro tion m uscles)	the till pression myes	em (  ssues ure >	PaO2 <	rerdos			E Equal	AL BLOOM
Hypoxemia:- 102 in Arte Tissue hypoxia:- 102 deliv Hypercapnea:- arterial Co depends on CNS (medu  NM-Junce (disphress 2 RS m	rial blood vered to 2 particular alla a phro tion m uscles)	the till pression myes	em (  ssues ure >	PaO2 <	rerdos			E Equal	y PH   PH   H   H   H   H   H   H   H   H
Tissue hypoxia: 402 delivery delivery delivery depends on CNS (media)	vered to 2 partial allad phra tion m uscles)	the till pression (N)  mye police Cuill	issues are >	50 m Drug of Stroke Traumors Tumors	rerdos			E Equal	PH H H H H H H H H H H H H H H H H H H
Hypercaphee:- arterial Co depends on CNS (media NM_Junce (disphress 2 RS m	2 particular phro tion m uscles)	mye  police	sthen	50 m Drug on stroke Traumors Tumors	rerdos 2. ves	e (opa		E Equal	PH P
NM-Junce (disphress & RS m	tion	mye polic	sthen	Drug of stroke Traumo Tumors Nie Gra	rerdos 2. ves	e (opa		E Equal	PH P
->NM-Juncs (disphress 2 RS m	tion m useles)	mya polia	sthen	stroke Traumo Tumors nie Gra	· · · · ves	E(ope		E Equal	PR P
(disphress 2 RS m	m  uscles) 	- polic Guill	L, 1 sthen	Traumors Tumors Die Gra	ves		7° E	ARTERIA INTEF  BROWDER   M P,CO., 9000, 6000-A0 fembooks   1 (97) 173 Actionals   70 A0 restated   6 (4) Actionals   70 A0 restated   70 A0	PH I H  AL BLOOI RPRETATI  COMPTION  FLOO, compt 16,700  FFLOO, compt 16
(disphress 2 RS m	m  uscles) 	- polic Guill	sthen	ie Gra	ves		V° E	INTER	AL BLOOK RPRETATI  COMPENSA  1 COMPENSA  1 P.OO. com a 16 P. 1
(disphress 2 RS m	m  uscles) 	- polic Guill	sthen	ie Gra	ves		AG AG	DESCRIPTION OF PLANTS OF THE P	T COMPENS:  # P,00, and * P,00, and the # P,00, and * P,00, and * P,00, and the # P,00, and * P,00, an
(disphress 2 RS m	m  uscles) 	- polic Guill	sthen	nie Gra	ves		-65 M	Acadosis situ/Delta* For AG metabolic s situ/Delta*	P.CO. = 0.7 v Name
(disphress 2 RS m	m  uscles) 	- polic Guill						Madesis   187   187	#P <sub>4</sub> CO <sub>7, wheel &lt; P<sub>4</sub>CO<sub>2, report blinds</sub> #P<sub>4</sub>CO<sub>2, wheel</sub> &gt; P<sub>4</sub>CO<sub>3, report blind</sub></sub>
		Guill					Page 1	espiratory : 187 187 espiratory : 187 187	Ander ( 9400 , ) 1 mm Otheric ( 9400 , ) 4 mm For each ( 90 mm Ander ( 9400 , ) 2 mm
			.cn Ki	esse S	nden	•		Pennary cleaneur (*5. comp gell 7.35 - 7.45, P.	erastion (\$7), arrows relative to "normal", ,00s, 35 - 45 resides and \$400, \$32 - 31
-> upper air		- I - I - I - I - I - I - I - I - I - I		hic Lat		alacae			
La lipper air		- ningi	этгорг	MC LGT	EIEL S	CIEIO			
	Way —	Disor					ies.		
		obstr							
		👆 infe	ction	(epigle	stite)	)			
		. forei	gn bo	dy ob	truction	on.			
		Lary		_					
		paral							
- thorax &	Algural			2100/	Lunk	acte R	دامه	mese \	
Indiana	PIEMIAL		iech si		יין כַּי	0) 1) 4	36011	11	\
		L- Fl	INCTI	onal (	CHUSI	on &	лем	THORS	*)
Alveolar	k parend	tymel		pulmoi	nally e	dema	CHE	·)	
			-	Lung f	brosis				
				COPD					
				ARDS					
mechanisms sulmaner	y: incer	ocity .			Dulma.	na rv	vslos		
mechanisms pulmonar	orfession	0	1110		T - 1111	9	7-15/1		
				م مالم			<b>.</b>		1
class la cellular	rar: far	E OF C	2 (SE	pric Sh	OCK, C	yarııdı	a bois	oning	<b>)-</b>
classification Acute	:- Suddet	eme	gene	T 1 PPH	(TCO <sub>2</sub>	180	2 , TPe	$CO_2$ ),	Tmor
chronic	:-d→M	, PH pre	serve	d (Thc	03), (	orpula	nonal	e po	yeythe
	(Hypox	(emic	RF)						
L. Type ?	II (Hype	Caphi	c RF).	,					



• Type I (Hypoxemic RF) Deff: PaO2 < 60 mmHg with normal or 1 PaCo2, + Acute disease of lungs. causes\_\_focal\_\_\_Atelectasis pneumonia 🔼 Lung Blad Diffuse \_\_\_ cardio pulmonary Edema. -non cardio-pulmonary edema (ARDS) -interstial pacumonitis or fibrosis \_infection. normal CXR \_\_\_ cordiac shunts \_Asthma, COPD [1] pulmonary embolism Type II (Hypercaphic RF). Deff: Pacoz > 60 mmHz, Hypoxemia always present - pH depends on LyL of HCO3 - duration of hypercapnic. Renal Response occurs over days to weeks. Acute\_\_\_\_ LArterial PH. - causes - Dry overdose (sedetive) muscle weakness (myasthenia gravis) Lung disease: ventilation can't maintained (Asthma/pneumonia) Acute on chronic .- Co2 retention (Copb) +9CO2/IPH (viral infection) causes --- RS center (medulla) dysfunction: Drug, cva, tumor, 173, central hypoventile NM-disease: Guillian-Barre, MG, polio, Spinal indagy -chest well/pleural disease - Kyphoscoliosis, pneumothorax, effusion. upper airway obstruction: + umor, foreign body, Laryngeal edema. - peripheral airway disorder: asthma, COPD. Diggnosis History --cough, dyspnea, chest discomfort, (fever, chills, rigors) .Acute & severe-tachypneac & can't talk clearly. . History taken carefully from pt. family & companions. History of allergy & Acute events. ng, cough, sputum - COPD pain, orthopnea, PND- HF+ pulmonary edema - cynosis physical tachypnea - paradoxical breathing & subcostal retractions

	Silent chest (tabstructi	on)				
	confusion . Somnolence & c		nvulsion	S		
	wheezes & crackles, Drog					
	wheezing (A/w obstruction)		chaspas	m.		
		MOOR	Maye	C Oice and	patholog	
					y edema	
	de la constant			Pulmona	7. Edema	
	Stridor: upper airway ob					
	+TJVP:- pulmonary HTN-		ysuncti	on.		
	crackles - pulmonagy ede	ma.				
-clinical &	Laboratory manifestations.					
Circula	ory: tachycardia, HTN or H	ypotentio	n.			
polycyt	emia (copo) :- chronic Hypox	remia —	<b>terytl</b>	voboieti	en.	
pulmon	ry HTN:- cor-pulmonale/1	Rt.V felic	ure.			
Laboratory	assessementABGs			FLOW 6-	VOLUME LOOP	
	Lung Fun	ction		5-	Г	GRAPH INDEX
	_ vitalogra			•- A		Post Graph
				3-	L	Predictions is
	→ c×R			F 8-		
	ECG			- i-	FEVI	
	Echocaro	lography		I o	i è	3
			ture.	B -1-		
	L, Bronchos	сору.		C -3-	1	
				-4-		
<ul><li>mangme</li></ul>	nt of RF					
	Hypoxemia may cause	death in	RF.			
	primary objective to r	everse &	preven	hypoxer	nia.	
	_ Secondary objective to	control	Pacas	& Tecoic	ctory acid	age .
	Tx of underlying cau					
			1 2	14-1		
	pt. cms & cvs must b					
9 1 99	L. Tarset: overcome hy	poxemia	by 02	, KO2	60, Ozsa	>40.
Acute RF_	ABC'S					
		<u></u>				
	Ensure airway is adequate					
	Linsure airway is adequated the construction of the construction o	d ventil	ation if	needed		
	Doxygen theraphy & assiste	d ventil	etion if	needed		
O3 The tasy	Oxygen theraphy & assiste Support circulation.	d ventil		needed		
O2 The rapy	Doxygen theraphy & assiste	ed ventile By essen	tial.			

	L	Not	forev	de	اماً!		lim	e fa	r C	OPE	<b>)</b> _	R	s d	epr	essic	n.					
Risks_		tox	icity		CN	is to	Xic	1 <sub>2</sub> 8	Se	iZu	res:	>	loss	mn	Hg.						
				L	Ca	pilla	ary	der	nse	,Le	ak i	g p	uln	non	जात व	Fabr	rosi:	: - L	eng (	Expo	Sui
				上	Re	rol	ent	al	Ab	901	asia	:-	401	>	50.				0		
					Re																
	→ Co	, nec	rosis		1	Peca	) )	, R	.ac	do	sis,S	oM	nol	enc	e,c	om	a.				
				L	tp	<b>CO</b>	2 5	<b>2</b> 01	nda	4	<b>.</b> C	ml	in4	tion	of.		No	Bre	eatl		
																	de				
Hypoxemia	(I):- (	2 (ne	sel,f	sce.	,inte	bal	ion	me	che	ink	u()	Pa	<b>0</b> 2 :	>60	m						
Hypercaph	ia(11)_	C	ontra	Lu	nde	di	15	Cau.	se							0					
		L, <mark>1</mark>	-3 L	./mi	n .t	ita	łe (	0,	Satu	rati	on :	>9	٠,	<9.	3 +	. 4	voic	h	PE	CAPI	nie
• mangsme	ent o	f se	ver	- Al	RF																
ICU (Ain	ev mc	Dame	n4)_	ETT	in	dic	eti	on s		Se	ver	Н	Pd	ken	nia						
	1	J		Ι.						Al	tere	J	me	nto	Ls	tete	es (	GCS	<8	).	
				Ι.	jM	Daf	en	_		7											
				7					re	May	re :	Sec	-eti					0			
											e ac					l:la	lian				
mechanica	/ ven	klaka		ind	lical														Co. 04	al.a	
→ mechanica	(MI	<u>/)</u>	"Г		Car	loit.	T				Con		usa.	200		ESP			July	9.	
	7,01,															وام:ما	4:-	Cau	7	.2)	
				C.	مالح			40	) PE		Da	CA-	<i>11</i> 3	EVE			3013	CPA		-27	•
			ľ	fu		_		D	103	P	m		lac								
								ve				LM)C	162								_
						ı r.	Н	Tr A6	114.1	410	<u>ر</u>		0.1	Ω	D.		7.		U.	(tox	
000				LOU	WES.	P	02	Th	ST C	SIVE 1	3	2 3	70	. 4	FA	2 2	700	MIN	ש' ע	TOXA	<b>C</b> 1
PEEP	MV_	<b>                                     </b>	antra 4	A -TI	no FA	EIC.	Pr	<b>235</b> 4	re	, ,	eep	Q I	(S)	9	pen	•					
		<b>L</b> , ↓	Shut 100	Min	,		as (	exc . '	hei	ye	•										
T2011/00	ype I	KP (	HK	<b>US</b> ,	pn	eu	Moi	nia 	). 00												
IPPV (CPF	Ib/R:	PAP)		mi								,									
			╁	»pt.	She	bild.	ha	ve_													
											erł		•			re	Flex	es .			
			┢	Ng	sal	or	Fell	fac	<b>e –</b>		10	W	ena	dia	٠.						
											Jw		of	br	ecil	in	•				
											10	0									
			1	Co		M.	11 .	L .	2000	•											


Tx of underlying cause: After tx of hypoxemia & hemodynamic stability Antibiotics: Pneumonia, infection. Bronchodiletors: COPD, BA ( Bronchospasm, airway resistance). Anticolinergics (Ibratropium brodmide) - COPD, BA (Lucyaltone, Relax SM). → Theophylline: COPD, BA (Idiaphragmatic contraction, Relex SM). Diuretics (fursemide) : pulmonary edema. metyl prednisone : COPD, BA, Acute esionophilic pn (Reverse bronchespeson, inflemon) Afliuds & electrolides. IV nutritional support (fat . protein 8 carb): restore strenght, Loss of muscle mass. physiotheraphy \_\_\_ chest percussion to Lossen secretion Suction of air wsg - Help to drain secretion maintain alveolar inflation (prevent atelactasis). weaning from (MV) \_\_\_ stable RS & CVS status - Adequate oxygenation, intact Respiratory drive. wake, good nitruition, able to cough & breath deeply. Complications of RF pulmonary pulmonary embolism Barotrauma pulmonary Fibrosis (ARDS) Nosocomial pneumonia CVS \_\_ Hypotention, LCOP \_\_ Arrhythmia L. MI, pericarditis GIt \_\_\_\_ stress ulcer, ilieus, diarrhea, hemorrhoje. infection \_\_ Nosocomial infection L. pneumonia, UTI, cath-sepsis. Renal \_\_ARF (I perfusion, nephrotoxic drugs). poor prognosis nutritional: malnutrition, Hypos lycemia, electrolyte disturbance. Prognosis: early tx - Tprognosis ARDS \_\_\_ 40% mortality (35% mild, 40% modrate, 46% sever). younger pt < 60 has better survival rate. - 75% -impairment of pulmonary function one or more years after recovery

5 - Anaesthesia	FOP (	EMI	S.	enz	4	Φ.	TR	RUJ	NO	1 (	e!					
· introduction																
Elective: - ahead o	time	. Na	nnec	1:04	win	ا <i>ا</i> ر	Jor.	nio.	. ^	de	se e	ļ 6	COL	el s		lon.
Emergency: Life-thr	cotonia	9 6	tant:		مامد		/ .	مادا	اعر. امرو		1	n o	ann	م	Luce	200
urgency: a state of	النحنجة	10	- C		\ \	11/14		2371	W CI		<i>j</i> . u	up.	4000	564		9
Trace Trace	Prioria	(60	ine r	acru	E).											
Types Traumatic	lia Cake	وعلما	/ N	leu c	140	امدها			C	C	<b>an</b> :		يص و و		· \	
Ton- Irania	IL CORS	161110	.esc., 1		, 04.		, 6		Ju	, 0	En	0-	un.	74	ZJ.	
Pre-operative pre	paratio	<b>1</b> 0														
Definitive trauma	interv	entic	06													
History & PE Reme	CAROCK	DEAC	ecos I	2 Dual	we lie		١.	OY	on!	lan	al	in				
- Insidigate active													ee			
							r	ne ne	. J				int	95.	أدم	٠.,
clinical intral issue			اء ما	ole.	<u>Q</u>	le c	ماده	HE		01 (	JUT	-op	10,11	EIV	'En/	
Cirricae infriae isiae	46	. 11.L.	9 0	1	7 0	- Jus		200	-41 -63)	•						
	pro	19	or pi	. TO	701	EIGI	E (		311	123	4. .l·.					
	→ BI	ever		or ny	POI I	ne i i	7114	:- •	Cof	Jul	4110	11 6	4 2C	40 E	•	
						, ,		1	1		la e .			1-		
Anachi acellarda	+c	1917	L	(acia	25i5 q	CO	Jeli	Per		T V	<b>a</b> 30	l T	301.3	LEPi	→ Lpre	Blusi
Anesthesiologist pa														0		
injury & Trauma:- 1	/. OF TOT	AZ TINC	ersia.	<b>es</b> , :	ra	11017		u)E	OF (	aes	m •	rte	F 61	VS A	La	•
Q uly pl. need	0.0000		6,,00	2												
How much time	emerje		suly C				9									
Signs of Hem					CITA	rion										
					· _ L	امر ا		1	. 2							
- guick airway ass						10)1	W D	7/01								
-, ventillatory Su	pport p	057-0	b i T		-/1		1		01							
TRecall memory: Box	we us			To ac	7	:He	27 (	·VS	, BJ	<b>3</b> T	<b>9 7</b> /4	onr	<b>70</b> [	•		
History & PE (SAMPLE)_		mpto														
1.1. 0		ergie														
Labs: During	-	dicat		, ,,												H
Resucitation		1	edica	<u> </u>												
if possible.			€ in												-	
	L. Eve	ents_	prior	to i	Ncio	lent									-	_

OR				
preprations_	Room should be as	werm as	practical.	
	IV flinds warmers	L rapid i	nfusion devices	
	pt. should be presun			ch - TRISK of aspiration
				iculty _Sibroptic broncha
				videolarynseosco
TV acess	usually in prehospital	selling	or emersency.	
	peripheral Iv line are	caliber &	quality for Blood	infusion - no need centre
	Hypotensive & Hypowlem			
	Subclavian V= CVL for Hy			
	ultresound:- Tsavily of		•	
	proximal tibia or hu			
111111111111111111111111111111111111111	Requires Bone proxim			
				Resistant in BM.
upon acciual	2 large caliber peri			
	Routine monitors _	•		Invaries monitoring
	induction & maintance)			An arterial line is helpful but not mandatory in the initial resuscitation of trauma victim.      Even with the assistance of ultrasonography, cannulating an artery in the
unesinencs (	Mauchon & maintance	Neura		presence of profound hypotension may prove difficult.  Attempts at placing invasive monitors can continue as the patient is prep for incision, to include gowning and gloving the person attempting arteria placement on the surgical side.
				Although arterial line placement may be a challenge, surgical incision can be delayed.     Surgical control of bleeding and Damage Control Resuscitation ( DCR) are top priorities in trauma resuscitation, not arterial line placement.     Stripping in this degree of hemocharmic companies on the presument for
			heral Nerve bla	have Trauma Induced Coagulopathy (TTC) and be in need of massive transfusion.  Attempts for arterial line placement can resume, and are more likely to b successful, as blood pressure improves from operative hemostasis and
	Handley allow (1		L Anesthesia.	resuscitative transfusion.  Having an arterful in is breeficial for monitoring the BP of the patient (especially during the arterial relation) and giving an idea about the hemodynamic stability and cardiovascular function determine the drugs and their doses, so part if invested as soon as possible
	Hypotention after (			itol).
	e-preserve sympathet			
	: 10mg - unresponsi			
	ine o.kmj:-IV, amnetic	= ,Hemody	namic unstable (†	Hemodynamic unstable in consciou
<b>A</b>   <b>V</b>	s of difficult airway			
Hypoxemic				
	upper airwey.			
	spinal cord injury in cerv			
Aspiretion	Head & neck trauma			
	pregrency, intestina	Lobstruct	tion , intra-abdo	minal mass, obesity.
	pain , childrens			
	L. Fasting time			
	-Adults : 2 (clear f	liud)-6 (	food) - 8 (Hevay	fatty meals).
	110 MILLS 1. 7 10.000 11			11104171

Rapid Seque	ence induction (RS	L):-aim is I Risk of a	aspiration.
		ust be confirmed befo	
		in or 4 vital breath	
	ined rapid IV indu		
			Curonium) without effect of induction .
tcricoid	pressure:-URisk of asp	iration (Risk of esophyeal	rupture).
Patient is a	not artifically ventilate	d.	
		racheal intubation for st	amach empluins
			00
Fliud manag			
			ts rather than crystalloid.
An messive	! Transefusion protoco	L should be requested	& followed
All fliuds	hould be warmed, ex	cept for platelets, Rapid	infusion -tcl-(Replaced).
		ors (18P-)freash clots.	
Analgesia			
7,101,01	titrated to the des	co of the of	Damage Control Surgery
Summary  Inadequate History and Investigations	<b>▼</b>		If a trauma patient requires emergent laparotomy for intraabdominal hemorrhage, the trauma surgeon will perform an abbreviated procedure termed damage control surgery [DCS].  Serviced interpretation is intended to stop hemorrhage and limit australisation.
Inadequate Preparation a- Not Fasting – Requires Rapid Sequence Induction of Anaesthesia	- Respiratory depression		contamination of the abdominal compartment.  After making a midline incision, the surgeon quickly searches for sources of bleeding through a quadrant eyaundarint examination.
Careful Choice of Anesthetic Drugs and Techniques c-Unavailability of Appropriate Investigations – Requires Depending	No NSAIDS For Hy		Definitive repair of complex injuries is not part of DCS.     Identification of injuries blood vessels and solid organs, as well as inspection of injuries in areas relatively inaccessible to midline approaches but potentially addressed by interventional radiology techniques (e.g. deep liver learentions, retropentioneal)
d- Unavailability of Appropriate Cross-Matched blood – Requires use of Type-Specific blood or Group O-Neg blood transfusion in life saving procedures until proper Cross-Matched blood is available	_Regional Anasthesia		hemorrhage), occurs during DCS. Hollow viscus injuries are addressed with resection, stapling, or both. Leaving the intestines disconnected until the patient is more stable reduces intraabdominal contamination and operatine time.
soring procedures after proper cross material about a disassic	_prevent Heat Loss (	delay recovery & extubation	Communication among the entire trauma team is essential during DCS. The surgeon must know if the patient is becoming unstable, hypothermic, or coagulopathic. The anesthesia team must speak up when there is a need to pause the surgical procedure to
• Post-op ma	negement		Damage Control Surgery
	tubation depends on	als have discourses	Pausing surgery results in the surgeon compressing or packing an area of
			Pausing surgery results in the surgeon compressing or packing an area of bleeding during times of protound hypotension until transfusion restores acceptable systolic blood pressure (8-90 mm hgl).  If this interruption of surgery is unsuccessful in improving blood pressure, the surgeon can directly compress the aorts. This intervention provides the surgeon direct Reddack as to the effectiveness of transfusion—a cut aort aort.
STADIE : Belore	extubation - Larryngosco	by -premove secretion.	suggests profound hypovolemia, whereas the return of a pulsatile aorta suggests a more acceptable circulating blood volume.  A brief episode of bradycardia/asystole may accompany direct aortic compression of the company direct aortic comp
	e & neostismen (Rev		When transfusions are ineffective maintaining perfusion, the operation should be interrupted, the bleeding areas packed, and a decision should be made between the surgeon and anesthesia team as to whether the patient can be transferred to the interventional radiology suite to treat bleeding from
		ıcy resiex -extubation.	surgically-inaccessible sites or to the intensive care unit where rewarming, correction of coagulopathy and hemodynamic stabilization may occur.  A key component of DCS is planned re-operation once the patient is more stable. At a later time, bowel continuitive can be restored or a colostomy can
continuation	of ventilatory (some)	).	be done.
→ICU → Sev	er chest injury.		
	lence of aspiration	pneumonia	
line	able hemodynamic	clatur	
Can	er Head in Jury for a		
→ SeV	r riega injury for	ELECTOR .	
— mas	ive blood loss with 11	nassive blood transfusi	on wan DIC.
L Pok	itrauma.		
• examples (	ATLS, caesrean sec	tion & Pediatric Burn	) → slide 38 → End.

## 16-principles of pediatrics anesthesia. introduction - chlidren not Little adults: different Anatomy, physiology, phermacology & psycology. Neonates (0-1m), infants (1-12m), toddlers (12-24m), young children (2-12y) TRISK of anesthetic morbidity & mortality (inversely proportional to age). prone to illnesses that requires unique surgical & anesthetic strategies. Resp. rate · Developmental considerations 100-160 CVS \_\_\_\_ Anatomic \_\_ Noncompliant Lt.V < 40 Residual Fetal circulation. Difficult venous & arterial cannulation. physiology \_\_\_ HR-dependent-Co (sv fixed) adominant parasympethetic (inhibition of cardiac function). Lable to respond to hypovolemia with compensatory vasoconstriction Blood volume \_\_ premature: 95 ml/Kg. -term: 90 mL/Kg -6w-2y:- 85 mL/kg 24 - puberty. 80 ml/Kg RS \_\_Almost all cardiac arrest due to respiratory problem. independent life is not possible until a gestational age: 24-26 w vs adults to three times higher than adults). eloped in neonates and infants techincal airway difficulties (0.5-17.). Twork of Breathing. Risk of edema: Small diamiter & airway resistance. JFRC:- JRs reservers -- apnea & Hypoxemia. Risk of endobranchial intubation.



Nea.			LI				ro																
PIE	oP	ryc	nol	ツ	Car		115						-	_						<b>N</b> -			
Ass	esme	nt o	f cu	ille	nt c	lini	cel	Stef	us d	all	evi	łat	e fe	crl	Q	xit	/ of	Chi	ld	X Fa	mi	y.	
	Shoul			مام	ina	4	L 1	L								0					١		
														.,									
<b>_</b>	evu	luste	. #	12	chil	d	Syc	olog	ical	S	atu	Z	Ja	ولاه	ir	ter	ecti	ons.					
	- L	<b>,</b>			•-	1	l		1	١	•	/^^	T#	<b>\</b>									
PER	entel	. pr	esei	nce	. IN	auc	tiol	1 4	nest	nes	Q (	LPP	Tu	<b>)</b>									
1-5	y:- <u>C</u>	omf	orta	Ыe	Se	Para	tion	n in	th	e	Hole	in	2 0	rea	us	uel							
- L.	):- <b>c</b> l		2		, c			ء اه		1	U:aa												
19	130		164	)		CU		Phi		70	707	•	1										
Phe	rmac	يوه ۱ه	j	M	id4	20	4M	:- D	.5 R	y/\	ار زي	sed	stia	n, I	5m	in e	nse	<b>t.</b>	ntr	ens:	klly	•cI	V.
				_ Ke	etai	min	۵.	P.	TA	Re	de	)	<b>2</b> 0 1	nin'	Rel	SP	ind	ucti	an.	15-	lom	./Ka	1
			П					40,					1.		0	1.		1.	- 11				, ,
					<b>L</b>	Dis	edl	/:- E	XC	essi	ve :	sec	reti	ons	4	ngi	IUCI	nqti	ons	•			
			يا	<b>pr</b>	opa	Fol	:- p	rop	er (	opt	en.												
				•			<b>'</b>	•		•													
				•				1	,		A		1										_
<b>&lt;8</b> 1	m :- 11	o se	Par	ctio	n a	nxi	y,	edu	ıcti	<b>SN</b>	oF .	Per	ent	3.			_						
Tad	dlen	:/ 1_5	2)8	Dr	ecd	hool	12	-5)	:- <u>4</u>	DLE	+ 4	he	n Sc	2 D Cd	de	<b>d</b> . 1	(tii	146	le n	ce)	).		
use	e to	ys ,	ac	CoTY	vbei	y (	per	ent!	<b>).</b>														
900	L:- <b>[</b>	a ppr	ehe	Sio	n , p	nd	uce	Se	de	ion	20	mn	esi	q.									
Day.	łe_	- 00			ممل	مام	11	<b>100</b>															
Kou	'E_	-> OF		01	aei	Ch	ICI	CII.				-	1.						)				
		Re	cia	.:-	pre	sch	ooL			•	Lon	g u	esti	Ŋ	PSY	Cha	legi	ceL	pre	ble	ms		
		J	4:-	Av	oid	2 <b>4</b>					2		(man	44	1	de	ctio	n.					
		7 -										•											
moi	nitor	ing .																					
BP		J																					
-	•																						_
Bloo	તે ડપ્	gar (	nec	na	le):	- 4	Jyc	98	n s	tor	25 –	<b>→</b> †	tisk	(of	hy	اووم	yce	Mia					
Dre	cordi	4 (	1041	hac	CoD.																		
	^					•														100 P			-
ECC	٠																		3			7	
Pul	se 0) 1P:-1	ime	ler	2	Cap	not	rep	hy.								1			1	1			
Ton	40	ا د د		0		J		0	06-	, L	-	_							2	1			
1511	rpi- I	<b>\EC1</b>	at.	153	P	7	eL.	111	4)0	7719	J <sup>n</sup>	۸		1					1				
H/h	y pr	essu	re	ma	mit	orii	19.												11.				
	c'_	LH	che	7	UD!										QCA.	2							
/	·	11.	7"			,	0 4																
		→Hį	she	1	in (	5m	4:	Ly.															
71)	ace			L	الر.	M _	11				100		۔ ایا										
	uce	<b>55≻</b> 17	169	DE	ai	ttCl	ALT.	or	EVE	:n_	1111	ا ال	1016									-	_
										_													
intr	raosse	eok	<u>5                                    </u>		Du	cin	, 4	dn	in s	tra	hion												
intr	raoss	eok	<b>5</b> _	_ <b>-</b> >	Du	cin	9 4	d n lecr	in s	tra	hion												

SVOFLURANE: most common and accepted. Fast induction HALOTHANE Greater Miveolar ventilation to FRC ratio. TCO to vessels rich organs (Brain). **ISOFLURANE** Ltissue blood solubility. **DESFLURANE**  URTI new or chronic symptoms? \_\_ infection/allersy/veromotor. viral 2-kw of GA with intubation t perioperative risk - wheezing:- xlo Laryngospasm: x5 Hypoxemia, atelectasis, recovery room stay, ICU. · Laryngospasm etiology:- superior Laryngeal N stimulation - involuntary Spasms. Risk - Extubated while Lightly anesthetized. - Recent URI \_\_Tobacco exposure. Tx \_\_\_ PEEP > locmH30 Laryngospesm notch. propofol: 0.5-1 mg/Kg IV -Succingleholine: 0.2-0.5mg/kg IV /2-4mg/kg IM. intubation · Peri-op pain control Regional (caudal): extradural block of intraumbilical procedures \_lanesthetic requirments - op & post-op utility. PO 10-15 mg/kg, PR 40 mg/kg, IV 20mg/kg NSAIDS (diclofenac sodium suppository) \_ caudel block is most common. Ketorolac 0.5-0.75 mg/kg IM/IV - Morphine 50-100 mcg/kg peripheral blocks & cath: Epidural, spinal. - Fentanyl 0.5-1 mcg/kg coudal peri-op NO HURTS WORST -Lepidural Pat may advance cath to theracic region - Ropivicaine 0.2% 1 cc/kg (up to 2 mg/kg) Bupivicaine 0.25% 1 cc/kg (up to 2.5 mg/kg) • Duramorph 25-50 mcg/kg • Hydromorphone 5-10 mcg/kg - Clonidine 2 mcg/kg


								.
• mal	gnant hype	erthermia:	Acute 1	ypermel	ebolic Stat	e in musck	e tissue	
Trigge	ering asents_	_Volatile	gents.					
		Succinyle	holine.					
Family	Hx muse	cle biopsy -	Caffine	Contract	ure test.			
0	± R	anodine re	ceptor	bnormalit	v.			
1Class	. A Plud a	1.0.						
nont	rissering	TIVA.						
	rissering T	Vitrous.						
_ trist	(Ducher	nne's musci	derdusta	aphy				
	central			9				
	-oste 95							
		enborough		<u> </u>				
Sien	sspecif	Reg	J TELC	or (pecly)	<u>,                                    </u>			
"0"		Rea	d then	p (late)				
			iscle nig					
		Phok	domyolo	esc Ach				
		0140	loburea	ois ucky				
	non-se	ecific	Tochac	ordio				
			Tocked	nea				
			Tackyf tk					
			Dysch					
				niaM	etcholic			
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 100	spiratory.			
					0			
L,T.	_Discontniu	a triaserin	a gent					
<b>~</b> ~ ~	- Hyperventi	المناهم المناك	4. 7 E					
	NaHCo3 1			2.				
	Dantroler Cool pl.	- 2.5 mg/	D 1.					
	Support as	indicated.	.:.	المسلم و	edlandae			
	_ monitor L				Jinni43.			
	1800 - Mi			ioring.				
	→ T000 - WI	1- N/   EK						

4						1.			1		n		. 11													
		Ш	16		UC	T(C	)/l		TO		Ш	16	511	12	510	4.										
•	de	ff																								
	Co	nsc	iou:	sne	SS > (	Our	con	Ini	19	stre	an	اه ا	aı	Jace	ne	50	f e	ithe	ro	ur	Sak	e la	adi	<b>195</b>	00	9k (
					L +																					
L	An	_			<b>—</b>	_			eli	19		se	NSG	tion												
<b>"</b>					,											an:	Scio	usn	ess							
						Can																				
												ra			10		, /	201	1.,,	٠, ١		->0	on.	Scio	us.	
												4	910	/	11	P 101		-la		ec l				scia		
	11		41.6	1	م دا	1.	-1																			_
┍	7	Pric	513	2- (m	e st		.1.	Pen	7	4) (E	ep I	4	Co	nse	zue	niy	u	n	72	OF	1	5	OUT	ronc	11.17.	<u>.</u> .
					on o															١,						
					Peir											xe	\$ (	ne '	alsy	iste,						
<b>-</b>  →					ate .							d	by a	dry	<b>3</b> 5.											
					ura							_					_									_
_					hiw																					
╌┝╸	Se	del	ion	·F	rom	911	yin	9 9	nxi	eļy	to	in	duc	נחו	ne	er s	leq	d	وريه	B	1	cer	ebr	gL (	znl	er
┸	ρα	in v	/s n	) o C I	cep	lion	) :-	Noc	cice	epł	ve	S	im	ulus												
																469	rdi	A,H	TN)	)						
					itale																					
Ľ	An	Xia	lysis	5	<b>—</b>	LAn	riel	y l	Fee	r. 4		zh	ensi	on	<b>2</b> ch	ess	).									
<b>'</b>			ð.,			Sed	anti			nr	مار	elc	R	.1 1	nx	alv		en.	off	art.	الم	b	an.	sed	alic	<u> </u>
							rys	. 1	+	-		20	re\			9										
	T.			-	ば:-	,				7	le .	1		J.,,		ala	300		Con	_						
					nt:																					
<del>       </del>	Mu	ISCI	e K	e IA	xatio	on:-	416	ens	e	7	to	ne	0	Pa	rely	Zin	3 Th	em	•							
	┝	ОЫ	ain	2 <b>d</b> 1	<b>n</b> —	-																				
					-		-054		ane	331/	162	iq_														
					_	-/	VM.	_ <b>J</b>	unc	tio	n	610	cK.													
	L	Us	ed	to	Fa	cilit	ate	V	en	ila.	lioi	1	<b>?</b> 0	pen	Su	ge	rie.	s , r	ee	d 1	<b>5</b> 1	1ec	han	ical	. ve	nt:
							_		Impo	ortant	Note	ıs II														
									notic se	datives	tranqu	uilizers														
							of	f consci		s, respi	iratory (	depres	ause los sion and													
							• TI	he diffe or sedat	rence b	etweer	drugs used fo	comm r intrav		d												
									of gen itic man		esthesi	a is the	9													

• General Anesthesia: -pt. has been rendered reversibly unconscious by drugs. used in poinfull op. \_ Diagnostic (MRI who had claustrophopia). Signs of back of concious :- Lacrimation, salivation, tachycardia, HTM end by: The or antidote. Triad of General anaesthesia Subdivision (Route):-IV, Inhalation, IM, Rectal Hypnosis Modren (Balanced) GA \_\_\_Hypnotic: Loss of consciousness -Analgesic : analgesia Analgesia Muscle relaxation MR :- parelysis. Stages (not on-off):-cumulative development of different clinical stages of conscious I (sedation) \_\_\_\_\_ Analgesia , 15.6 & spinothalmic. no amnesia. → Linhibitory (solzi II) → Facilitation \_II (Delirium)\_ excited but amnesic irrugular Respiration rate. Retiching & vomiting. \_\_incontinence & Struggling. Cummulative dose of Hypnotic drug Regular Breathins - End. Brain is painless tissue Anesthesia level should match stimulus 2% of patient reach coma 2% of patient stay at sedation level III:-depression of RAS + Ispinal reflex (MR). Rujular Breathing -- complete cessation of Spontaneous respiration. plane 1:- return of regular respiration -> cessation of REM. - plane 2:- Surgical plane, cessation of REM - onset of paresis of intercostals. plane 3: onset - complete peralysis of intercostals. plane 4: paralysis of intercostals - paralysis of disphreym (apneic) →IV (medullary depression): cardio-RS collapse -> coma & death. alistinctive signs Repid onset of action drugs. \_ mechanical ventilation · Work In Every Area Of Medicine pre or intra-op drugs - influence the signs of anesthesia. - OR, PACU, ICU, OB, Peds, Pain Clinic Work With The Most Diverse Patient - Premature Infants To Geriatrics Ether Day - October 16th, 1846 · Provide Medical Care & Critical Care Prior To, During, And After Surgical rovides medical care to each patient: Work With Advanced Technology celing and informed consen ing life functions during surgery. sing immediate post-operative care You Might Like Anesthesia If... Anaesthesia is now very safe · You Enjoy Performing Procedures Brief History with mortality of less than 1 in You Are Interested In Critical Care 250,000 directly related to You Enjoyed: anaesthesia. Before anesthesia:... - Pharm, Physio, Cardiology, Pulmonology =======cf.======= You Like All Areas Of Medicine The global mortality rate due to traffic accidents You Like To See Immediate Results was 19 per 100 000 population (1:5263) Surgery was a terrifying last resort in a

· Pain and Narcotics. · introduction (deff) TASP: unspleasant sensory & emotional experience associated with actual or poteinful tissue damge (Functional pain: without tissue damge (IBD/Fibromylagia)). personal experience induce by Biological, psyco & social factors (differs blu pt.). Through their life experiences, individuals Learn the concept of pain. pain should be respected. pain has adverse effects on function & Socia-psycho well-being. \_verbal description & non-verbal (tachycardia, Hypertentian). Noxious:- unpleasant. Noxious stimulus:-stimulus damping to tissue (not all feel as pain). Nociception: The neural process of encoding noxious stimuli Nociceptor: 1-Threshold sensory receptor of PNS capable of transduction & encoding stimuli. Classification - duration - Acute (<120), chronic (>120) -physical origin: Visceral, sometic, refered. - cause: - cancer, inflammatory, post-op, mechanical. mechanism - Nociceptive - danging of non-neural tissue. Neuropathic:-Lesion or disease of sometosensory (CNS) Nociplastic : not either (IBD+fibromy)esia). Anatomy > Physiology Transduction: tissue damging stumli activate Nerve ending (AP) - CRA delta fibers. Mechanical (pressure, pinch), Heat, chemical (Hp. Badykinin, PGEz, Na,K, H, sentonin - R - dep cell inflammation: TNF-x, IL-1826, NGF - CRA-delta fibers peripheral sensitization-decrease thershould of nociceptor - Topinful sensitive

									L
- Transmi									L
PNS:	- AP is prop	yated to	CNS by fl	ne first o	ider neur	on.			
Each	stimulus ge	nerate a	pettem &	Grezuen	gy (code				L
	-1st +2nd or						Cyrsy Ha	m)).	L
	cotransmitters								<b>e</b> )
	ptors : AMPA								Ľ
	othelamics			usco	rtex.				
	ion:-The sub					signals:	it involv	es the	
	ration of ma								
Module	ion — Lac	trity of co	cending po	thways b	ridesendi	ns pethe	aus_10	ein.	
	ion — tad	emicals :.E	ndeteneus	opioids (1	Endocahin	Enkephali	n).Serator	nin . Nor-A	4
Acute pair	•								Г
DeffP		chimanlus (	معناء بصائمة	(0) <3-/	La dicce	per afte	r tians	Heclins.	Г
	lerm system							7	Г
	lociceptive			al Celara	المورامول	\ dees	Cache no		1
	J. Cepive	viscere	/ . d.fr	o color	Cod Dala	, , ueep	Carles VIII	,-05041132	
Systemic Re				EVIEREI	ied pani.				r
				Lililia a		dala ur			T
06 41	M. tachycardi tal body Oz	Cane	BIRL HITT	only M	Time Precip	ITATE MIL			H
					TiON.				H
	nary:-ilieus								H
	ne:-Tcatabo		ues a ta	nebolic h	ormones.				H
History —									H
	-Known Cau								$\vdash$
	- medicatio					PAIN	SCORE 0-10 NUMERICAL RATING	G 9 10 Wang	H
Assessment		4 1					paan	positive	H
		_, VAS (					Vertal Rating State IVRSI	worst possible pain	H
		L-VRS (		erbal ra	ting scale	No puls	-NIBO 3400CF30 <sup>2</sup>	Kente ball	H
	<b>└</b> → peds —	→NRS (S	-8h)				PAIN SCORE 0-10 NL	JMERICAL RATING	-
		wong-	Baker F	ACES ret	ing scale		And Proph	grade 2 0 2 10 Weers to provide provide	_
		FLACC	BcKer F (m-7y				0 2 4 No Usb Bit Usb	6 8 10  Brants Burts Whole Loil Weet	_
		-				The FLACC pain scale sometimes it is difficult to assess poin in chill a system that can rebip several and primition or no expression communication. The slages for primition or given to each of the fore called the primition are given to each of the fore called to primition.	Little Motifs  Street who are non-verball. The FLACC pain scale is not assess pain levels in children who have freithed where the salespense for scaring. Zero, were an effect leading with the salespense for scaring. Zero, were an effect leading and commissioning.		_
						Each calegory is served on the 0-2 D relevad and confortable 1-3 relial discontinuit.  Categories Serve and Catego	the Behaviour Score seeds, which results in a trief score of 9-10, 4-0 moderate pain. 7-10 senses disconduct of pain or both Green even. Green even. Frequent to constant		_
						A Activity profession or smile of the control of th	antholisms, characteristics and constraint of the Control and Jac.  Unusary, readines, tennes.  Kalding or large almost specificationing, anthrong basis.  Accept, facilities or large almost specification of the control and		_
						F a Chib is showing these behaviours pain as same of the behaviours measureach. However, parents are solvier	Nameurous lity orientational providing August or being staken by distributable or combine to combine to the providing and the providing providing to the providing and the providing providing to the providing and the providing the providing to the providing to the providing to the providing to the providing to the providing to	Bit for CIDE C  Stockell M. Vergelf-Lewis T., Happeria JE., Nidelya K., COCC What FARCH Inhancioural scale for senting proseposable pain in pressy shillness. Publishs Plening 3505, 500-500	L



		Route	es of adm	inistartio	n	
L Morphine		Orally: Morp	hine, Buprer	norphine (hig	h first	
onset:- 1-2 min IV		<ul><li>pass effect)</li><li>Transdermal</li></ul>	: Fentanyl			
pesK:- 3omin		Transmucosa	al: Buprenor		yl	
Metabolism:-Liver (coasation), Kidn		Epidural: Mo	orpnine, tent	anyi		
MCTSpalism:-Liver (Cosystion); Kian	70					
MGG (10%) of morphine metabolis	e a more po	otent on	r. rec	eptor.		
SE:-Renal dysfunction						
	TABLE 31-5 PHYSICOC	HEMICAL AND PHARMA	COKINETIC DAT	A OF COMMONL	Y USED OPIOID	AGONISTS
FentayL		Morphine	Fentanyl	Sufentanii	Alfentanii	Remifentanii Short
Duration: - 30 - 60 min.	PK₃ % Un-ionized at pH 7.4	8.0 RCA	8.4 <10	8.0	6.5	\$7.1 Wasan
metabolite: Norfentanyl	Octanol/H <sub>2</sub> O partition coeffi	A STATE OF THE STA	813	1778	145	17.9
Loading dose (+induction):- 2-6 /3/16	% Bound to plasma protein Diffusible fraction (%)	20-40	84 1.5	93 1.6	92 8.0	80? 13.3?
	t <sub>ha</sub> (min)	1-2.5	1-2	1-2	1-3	0.5-1.5
Alfentail	t <sub>Viβ</sub> (min)	10-20	10-30	15-20	4-17	5-8
	t <sub>Vry</sub> (hr) Vd <sub>c</sub> (L/kg)	2-4	2-4	2-3 0.2	1-2 0.1-0.3	0.7-1.2
faster than 2	Vd <sub>ss</sub> (L/kg)	3-5	3-5	2.5-3.0	0.4-1.0	0.2-0.3
spotent than 2 , ICU.	Clearance (mL/min/kg) Hepatic extraction ratio	15-30 0.6-0.8	10-20 0.8-1.0	10-15 0.7-0.9	4-9 0.3-0.5	☆30-40 ☆NA
SufentaniL						
x2 Lipid soulble & thound to plan	me proteins	Car-geld	Nycon	tein)		
more potent than 2.						
mais polen man 2.						
Remifentanil						
structure :- ester Linkeses.						
Holyrolysis by Blood & fissue estra	ses-Rapid	metabolism	us us	ed in l	kidney/	Liver fe
Emersence.						
not influenced by pseudocholines	strase defici	iency.				
opoids Antagonists						
reverse Respiratory depression	_ \\a	oxone/	Malla	PYONE		
nauses & vomiting.						
		Receptor:-				_
purifis		E				edema.
urinacy retention.		nset:- 1				
		78.4 I	1	70.4		lace nee
Rigidity		.''2 :- <mark>3</mark>				
		Short !				

• 5h	ock												
•	I. I												
	duction												
why	to Learn	about s	hock?										
	ife threat	ening en	tersend	y the	may	be rev	ersible	if a	propri	ctely	re casn	ized .	
l l c	olden Hou	c - critica	/ to 0	and a	dven	e out	AMP	(Mar	ia lile				
									0				
						. aala I							
→Def	inade	eguate pe	rfusion	of tis	sue ('	affil)	Merca )						_
	Path	physiology	related	to th	e dete	rmina	nt of C	), del	ivery	(Co,u	oscular	integr	ily)
Epide	emiology	/pathophy	sso)ora	(4 +	upes	<b>_</b> ).							
	00	טיייי	d.		7								
20	o . T												
	& symplo												
	referentia												
S	ress hormo	nes:-catec	ho ,corti	ioL,ant	iduriti	ic,RAA	S→pr	eserv	e fliuc	Volu	me (tal	serpli	on).
	·3o% Loss o	f volume	→ en	d org	en de	muse !	& cel	lular	death				
اماند	s — Tem	o. Faver	مد لاسم	. Har									
V1/41		A. II.		- I			100	( a.	un.				
	→ MK-	t in Hy	potensio	II to	comp	enscre	42V	(CO	SHK	KSV).			
		Norma								genic	Shock.		-
	BP:-	Hypotent	ion MI	AP<6	Smal	7 (B	P = C	٥xSV	R).				_
	RR:	- Tachypr	ea Co	mmon	<u>ly</u>								
	Li Pa	- preserv	ed by	o. ex	trecti	an 1:	-Late	Store	1 1o	veale	rfusion.	.	
			J										
٤		00000											
Exan	nination (	HRCDE											
			┝	reethi	ng:-eg	val so	ands c	on Bo	th Sid	es.			-
			_ <b> </b>	ircula	tion :-	perip	heral	Pulse	<b>s.</b>				
										8 →in	lubation	(145p	icatio
											volume		
								7	- PE	7,10117			
ء ام								G	LASGOV	/ COMA	SCALE(GCS	5)	
Cun	ical pictu ishs of of	ire may i	KMAE						Behaviour	4. Spontaneous	sponse	+	
<b>→</b> 5	ishs of ot	zen hypo	perfusio	<b>n</b>				_	Operator Bessesse	To speech     To pain     No response			
<b></b> ^M	ultiorsen	Dysfuctio	n Synd	lome	(No	<b>DS)</b>		Ev	Cycling desponse	<ol> <li>Confused</li> <li>Inappropriat</li> </ol>	time, person and place	De.	_
<u> Li</u> R	esult is:	end orsa	n Faliu	re.					Verbal Response	Incomprehe     No response     Obeys comm	nsible sounds		
				1				1	-	5. Moves to loc 4. Flex to withd 3. Abnormal fle 2. Abnormal ex	fraw from pain exion		

	olemic Sh					<b> </b>	-			
→Deff:-↓i	ntravescular	Volume						ins , diem		
			<b>L</b> →B	lood los	s:-CI	bleed,	Post par	łum , AAI	9,Hemof	rtysis .
_classI_	_750 ml (15)	<u>()                                    </u>					ı İ			١, ١
	- compense	*	anlad			Class	ses of 1	Hypovol	emic Sh	ock:
							Class I	Class II	Class III	Class IV
	HR,BP,urin		r are	MqiATqi	ned.	Blood Loss	< 750	750-1500	1500-2000	> 2000
—Cless <b>∏</b> —	+1500 mL (	, <b>30%)</b>				% Blood Vol.	< 15%	15 – 30%	30 – 40%	> 40%
	THR (co=	HR×sv)	, mild a	nxity.		Pulse	< 100	> 100	> 120	> 140
	BP & urine	1 1 7				Blood Pressure	Normal Normal	Normal Decreased	Decreased Decreased	Decrease
	•			_		Resp. Rate	14 – 20	20 – 30	30 – 40	> 40
*	1500 - 2000			<b>'</b>		UOP	> 30	20 – 30	5 – 15	negligible
	- LBP& urine				+++	Mental Status	sl. Anxious	mildly anx	confused	lethargic
	Need repl	ccement	(Bloc	d or fli	uds).	Fluid	crystalloid	crystalloid	blood	blood
	PE (dehydro					nu da	MHCAH	ممالوه و		
· class TV	>2000mL	(510-7)				ن م				
				1						
	Lethersic									
	Tachycardi	a will be	e pros	ninent	ecture	of sev	er Shock	l before	e hypote	ntion
		ess III ta								
0:										
- Diagnosi	S - History	/   <u>.</u>								
	<b>₽€</b> :- C	old Sho	cK pic	ture a	pellor.					
	HSL & H	cT 1 . 1	Vorma	L Het-	flind	Loss, H	cT is be	tter.		
	Metabo									
		""								
								pic -> L		
			_ <b>L_</b> } F	lencl f	unction	r: ure	2 > 2 om	1/dL, tp	aramete	rs .
	Cogsular	tion:-PT/	TMR P	TT, Fibria	-osen:	tclot	reskd	wn (fibre	lysis) - Co	egulope
	SVo2:-	•								
	imssing	1 + + C	xK, Pe	lvic-Xf	GA ' DZ	CILS	redie pt	<b>7</b>		
		<b>_⊢</b> ↓A	nsiagi	rephy :	Locali	ze So	urce of	Bleeding:- Free	19.	
			irect o	eritane	al ase	iretion	Levese	- Free	blood -	aprote
Ty R	eplac <mark>ement</mark>	lov to t	ume '	+ treat	the	cup /	14 00	6 sauce	IV)	
								7 3 3 9		
	BCDE if A					-				
<b> </b>		A 2 2	<b>L/K</b> 9 6	every S	-lo mi	r up to	1-2L)	or coll	olds	
A	rystelloids (	.20-30 m			•			V		
A	rystelloids ( lirected th	eraphy	u	rine ov	tput :	· >0.5	ML/N3	/Hr		
A	rystelloids ( lirected th	eraphy	u	rine ov	t <b>put :</b> 8_12 =	· >0.5	ML/ Ng	/Hr		
A	rystelloids ( lirected th	eraphy	u	rine ov :VP :- 1 IAP :-	t <b>put</b> : 3-12 r	>0.5 nmHg.	mL/ng	/Hr		

	l . L	<b>.</b>	٠١/																	-
2 Distri	-			l	<b>. 4.</b> -				LI.	١,		ale	<u>/1</u>	CVII	• •					
→ Deff·in																LC				
			epsis:- eptic s																	ı
<u> </u>	THE PARTY OF THE P		spine 3	DOCK	· we	. I Off	7	DF	3	E	7	23O	16)	OI					2mmal	
D	athoph	rsiology:	infec	ion r	elace	Dra .	2 0	nt:	inf	lam	Me	af u	CAC	Pan						
	Macha	photes	2 new	took	ا داد	Susta	Mic	c a	lter	etio	Λi	n De	erfu	fia	1 . 11	ies	ocir	cul	ctio	1
		leath &																		Ĺ
D:		SIRS).																		
	.,,		N																	
				<b>R:-</b> >																
			_, <i>w</i>	BC:-	712	900	or	<b>~</b> 4	000	•										
			L,	pres	umed	exi	iter	nce	of	inf	ecł	ion								
T	ر <mark>ہے ار</mark>	ection	Sour	ce c	ontro	L÷	cul	tur	e_	• an	tibe	tic:	s (L	ithi	n 1	hr)	20	leii	n q Je	
•	R	esuscita	tion &	Life	Suppo	<del>/\</del> _	<b>—</b>	Fli	ud	Mel	zm	ent	-	Bon	nL/	K	in :	3hr		H
								Uri				- 0	.5 m	L/V	. وا					H
		sopres						, Vq	sop	ress	in.									-
		echanic																		
	_ <del>L→</del> Re	mal rep	placen	nent	thers	Py:-	AKI	[ (1	K,a	cid	osis	, ur	emi	42	volu	me	ove	rloq	d).	-
77\11		1																		
→II) Nei	ıroge	nic Sh	ock																	
Deff	<b>→</b> !!	emody	nemic	c ch	enjes	From	n S	udd	en	os	of (	auto	100	ViC	ton	e (	abo	ve	18)	Г
		othing																		
		. ce											•		•					•
	L>81	pinal sl	hock:-	Loss	of a	II sei	nse	ion	60	lou	<b>#</b>	e L	yL	of i	NJų	tk (	not	CifCu	laton	)
Dx:- 1							ned	g	, с	) 0	r M	KT	•							
lx (Su	pportiv	e):- <b>[</b>	uds 4	pres	sors.															
→III)Ana	Shulati	c shoc	V																	_
		lergic re		n lin	mune	Jacio	al e	200	an co	40	anl	: 10	nel.		l:d	~ ~	ine.	T.	- V	
- DEIV		rect acti																		_
		oth are			•		1			•								751		
Vasad					- 1181	11.02		761	-"		-	<b>46</b> [		<b>,</b>	-11	9.				
7 - 100			ciel &	•	se su	ellin	15 -	<b>→</b> Δ	n e	<b>.</b>	om/	) far	nis/							_
			nche	1					-					•						
			-115/10	4310				7.												

	)×,,	cli	rica	L.	LBP	.11	IR.	Res	12	itch	in 9	an	Sio	ede	Ma						-			
		An																			6		5	
т	×																							
	<b>*                                    </b>	310	PT	ne		<b>203</b> [	lle.	70	INE		Jei									_	A	ngioedema		
	┢	Aic	rwę	<b>y</b> :-	ans	ioe	der	ng.		eri e	y E	17 &	U <sub>2</sub>	+ m	oni	tori	y.							
		IV																						
	$\rightarrow$	*E	pine	pho	ine	(0	.ol	_0.	<b>0</b> 5	my.	ΙV	or I	M)	<b>&gt; e</b> 1	/er	y 5.	.15 m	in -	lo n	min	tein	M	P>	15.
		All																						
		H <sub>4</sub>											ľ											
		ste		_						ما		all.		1				موا	. 0	200		<b>CO</b> 4	.L	
	<del>     </del>	STE	11 O)(	33 (	HJ°	1100	.01T	Dør		ae.	AGIII	ETA	<b>9 7</b> 0	le):	<u>- 41</u>	C	<i>y</i>	E		JEI	/EI	16	LITE	, , , , , , , , , , , , , , , , , , ,
[2] al.	1.	1.		al																				
306	.																							
<b>→</b> Defl	: ob	stru	ctio	n o	f H	ecr	t o	r G	rec	V	esse	ıls -	<b>-&gt;</b>	Co	-	Jρ	erfi	uSic	n.					
exan	ples.		Ten	Sior	۱ p	neu	Mo	tho	reX	:-+	rgui	M4,	hyp	oxer	NJA	. (n	ridel	avi	cula	r 2	nd i	nte	rest	
	•		per																					axille
			a.l						11		100	1	L	(an	l:a									9
												7516	<b>.</b>	(an	16	الح	11911	911/						
		Ь	Res	tric	tive	C	A (Q)	out.	/op	thy														
	1																							
141 Car	diago	eni	د د	ho	٤K																			
Deff		fal	iure	2	! th	e p	uM	p,F	CS	,me	che	nic	aL	fali	use	20	rch	the	ala,	MI	,m	100	edi	tis.
		14																						
Dx_																	J							
			Ec																					
		П	1			_			г .															
		Н		•										ngir					١.					
														ein,	hai	rd, b	acK	, ep	iser	fic ,	, Jer	pe	in.	
L→Tx_	<b>→ A8</b>	Cs +	·IV	<b>4</b> C	ess	Z i	N VE	sive	Ы	ood	m	onid	orin	١										
	me	dic	atio	ns.	_	Ası	pici	n 3	25	ms	21	lep	arin											
														lory	ы	th.	NS	EM	T.					
	→ Pre	ff.a.	. 1			_	1	•																
			-10	10				1		100	EP	-7												
	→ PC	-		14	n o		ym	РТО	MS.	(51	EM								١.					
			-	CG	nno	+ 6	e q	dmi	nisł	red	in	12on	ůn.	-	P:b	roly	tic	the	rap	y				
				dil	Juc	ult	PC	I.	-	CA	BG			-		Ĭ								
	_Me	che	nic	aL	Sup	Pol	<b>†</b>	int	ra -	Aor	tic	Bal	lon	Pun	1P	(Ja	BP)	)						
					•									ľ	•				Go Airway p		Shock	k Res	uscita	tion
																		:	Control Optimiz	Work of E	ation			
																		Η.	Goal-dire	s of Resus cted thera uide therapy	ipy: Use obj	ective hem	odynamic a	nd physiologic
																		H	<ol> <li>CVP</li> <li>MAP</li> </ol>	output >	-12 mmHg 5 to 90 mmH	lg		
																		H	4. Centr	al venous ox neral, s			<sup>™</sup> <u>treat tl</u>	<u>1e</u>
																			caus					-